A

Access DB# 65460

461

SEARCH REQUEST FORM

Scientific and Technical Inf rmation Center

Requester's Full Name: PATEL SUDHAKER Examiner #.: 77018 Date: 4/29/02
Art Unit: 1624 Phone Number 30 84789 Serial Number: 10019693
Mail Box and Bldg/Room Location: CM1 4E18 Results Format Preferred (circle): PAPER DISK E-MAIL
4E12

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: PHENYL SULFAMATE DERIVATIVES

Inventors (please provide full names): NAOYUKI KOIZUMI et al

Earliest Priority Filing Date: 7/6/1999

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



RECEIVED
APR 26 2002

****

STAFF USE ONLY

Searcher: BOB
Searcher Phone #:
Searcher Location:
Date Searcher Picked Up: 5-6-02
Date Completed: 5-7-02
Searcher Prep & Review Time: 40
Clerical Prep Time:
Online Time: 45

Type of Search

NA Sequence (#)
AA Sequence (#)
Structure (#): 4
Bibliographic
Litigation
Fulltext
Patent Family
Other

Vendors and cost where applicable

STN 593
Dialog
Questel/Orbit
Dr.Link
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

RECEIVED
APR 25 2002

PTO-1590 (8-01)

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L1    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10019693 (patel - amended).str

L2      STRUCTURE UPLOADED

=> que L2 NOT L1

L3   QUE L2 NOT L1

=> d l3
L3 HAS NO ANSWERS
L1              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L2              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3              QUE  L2 NOT L1


=> s l3 sss sam
SAMPLE SEARCH INITIATED 17:20:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    213 TO ITERATE

100.0% PROCESSED     213 ITERATIONS                          2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3385 TO     5135
PROJECTED ANSWERS:               2 TO      124

L4            2 SEA SSS SAM L2 NOT L1

=> s l3 sss ful
```

```
FULL SEARCH INITIATED 17:20:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   4194 TO ITERATE

100.0% PROCESSED    4194 ITERATIONS                          63 ANSWERS
SEARCH TIME: 00.00.01

L5            63 SEA SSS FUL L2 NOT L1

=> s l5
L6           17 L5

=> d l6 1-17 bib,ab,hitstr
```

L6 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:312347 CAPLUS
DN 139:30177
TI Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors
AU Winum, Jean-Yves; Vullo, Daniela; Casini, Angela; Montero, Jean-Louis; Scozzafava, Andrea; Supuran, Claudiu T.
CS Laboratoire de Chimie Biomoleculaire, UMR 5032, Ecole Nationale Superieure de Chimie de Montpellier, Universite Montpellier II, Montpellier, 34296, Fr.
SO Journal of Medicinal Chemistry (2003), 46(11), 2197-2204
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB A series of sulfamates or bis-sulfamates incorporating aliph., arom., polycyclic (steroidal), and sugar moieties in their mols. has been synthesized and assayed as inhibitors of the zinc enzyme carbonic anhydrase (CA), and more precisely of the cytosolic isoenzymes CA I andII, and the transmembrane, tumor-assocd. isoenzymes CA IX. Some of these compds. were previously reported to act as inhibitors of steroid sulfatases, among which estrone sulfatase (ES) and dehydroepiandrosterone sulfatase (DHEAS) are the key therapeutic targets for estrogen-dependent tumors. Very potent (nanomolar) inhibitors were detected against the three investigated CA isoenzymes. Best CA I inhibitors were phenylsulfamate and some of its 4-halogeno derivs., as well as the aliph. compd. n-octyl sulfamate. Against CA II, low nanomolar inhibitors (1.1 - 5 nM) were phenylsulfamate and some of its 4-halogeno/nitro derivs., n-octyl sulfamate, and estradiol 3,17.beta.-disulfamate among others. All the investigated sulfamates showed efficient CA IX inhibitory properties, with inhibition consts. in the range of 18 - 63 nM. The best CA IX inhibitor detected so far was 4-chlorophenylsulfamate. These data are crit. for the design of novel antitumor properties, mainly for hypoxic tumors that overexpress CA IX, which are nonresponsive to radiation or chemotherapy. The antitumor properties of the ES/DHEAS inhibitors in clin. trials may on the other hand also be due to their potent inhibitory properties of CA isoenzymes involved in tumorigenicity, such as CA II and CA IX.
IT **25999-01-3P**, p-Biphenyl sulfamate
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(carbonic anhydrase inhibitors. inhibition of cytosolic isoenzymes I and II and transmembrane, tumor-assocd. isoenzyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:103675 CAPLUS
DN 139:193408
TI Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES)
AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.
CS School of Chemical and Pharmaceutical Sciences, Kingston University, Surrey, KT1 2EE, UK
SO Journal of Steroid Biochemistry and Molecular Biology (2003), Volume Date 2002, 82(4-5), 425-435
CODEN: JSBBEZ; ISSN: 0960-0760
PB Elsevier Science Ltd.
DT Journal
LA English
AB We report the results of our study into a series of 4'-O-sulfamoyl-4-biphenyl based compds. as novel inhibitors of the enzyme estrone sulfatase (ES). From the results of the mol. modeling design process, it was suggested that these compds. would be able to mimic both the A and C rings of the steroid backbone, and thus possess inhibitory activity against ES. The results of the biochem. evaluation study show that these compds. are indeed good inhibitors, possessing greater inhibitory activity than COUMATE, but weaker inhibitory activity than EMATE or the tricyclic deriv. of COUMATE, namely 667-COUMATE. Furthermore, the compds. are obsd. to be irreversible inhibitors.
IT **25999-01-3P**
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and reactant; design, synthesis and biochem. evaluation of AC ring mimics as novel inhibitors of estrone sulfatase)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT **319014-71-6P 319014-72-7P 471269-63-3P 471269-64-4P 471269-65-5P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis; design, synthesis and biochem. evaluation of AC ring mimics as novel inhibitors of estrone sulfatase)
RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 319014-72-7 CAPLUS
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:44124 CAPLUS
DN 138:55747
TI Preparation of arylsulfamates as estrone sulfatase inhibitors
IN Ahmed, Sabbir
PA BTG International Limited, UK
SO Brit. UK Pat. Appl., 28 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2371299	A1	20020724	GB 2001-1220	20010117
PRAI GB 2001-1220		20010117		

OS MARPAT 138:55747
AB Title compds. [I; R1-R5 = H, halo, alkyl, nitro, (substituted) alkoxy, aryl, aryloxy, alkylamino, arylamino, COOR6, sulfamate group; .gtoreq.1 of R1-R5 = sulfamate group, aryl, aryloxy, or arylamino substituted with a sulfamate group; R6 = H, aryl, or alkyl], were prepd. Thus, NaH was added to a stirred soln. of Me 4-hydroxybenzoate (prepn. given) in DMF at 0.degree.; after 30 min. aminosulfonyl chloride in PhMe was added and the reaction allowed to stir for 10 h to give 31.6% Me 4-[(aminosulfonyl)oxy]benzoate. The latter inhibited estrone sulfatase by 74.7% at 50 .mu.M.
IT **319014-71-6P**, Methyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-63-3P**, Ethyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-64-4P**, Propyl 4'-[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate **471269-65-5P**, Butyl 4'-[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylsulfamates as estrone sulfatase inhibitors)
RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:482277 CAPLUS
DN 138:66153
TI The design, synthesis, and biochemical evaluation of derivatives of biphenyl sulfamate-based compounds as novel inhibitors of estrone sulfatase
AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.
CS School of Chemical and Pharmaceutical Sciences, Kingston University, Surrey, Kingston upon Thames, KT1 2EE, UK
SO Biochemical and Biophysical Research Communications (2002), 294(1), 180-183
CODEN: BBRCA9; ISSN: 0006-291X
PB Elsevier Science
DT Journal
LA English
OS CASREACT 138:66153
AB We report the initial results of our study into the use of a potential transition state (TS) of the reaction catalyzed by the enzyme estrone sulfatase (ES) in the design of a series of simple 4'-O-sulfamoyl-4-biphenyl-based compds. as novel inhibitors of ES. The results of the study show that these compds. are: potent inhibitors, possessing greater inhibitory activity than 4-methylcoumarin-7-O-sulfamate (COUMATE); weaker inhibitors than the tricyclic deriv. of COUMATE, namely 667-COUMATE and the steroidal inhibitor estrone-3-O-sulfamate (EMATE), and irreversible inhibitors of ES.
IT **25999-01-3P**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT **319014-71-6P 319014-72-7P 471269-63-3P**
471269-64-4P 471269-65-5P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)
RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 319014-72-7 CAPLUS
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:324919 CAPLUS
DN 137:310661
TI Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES)
AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.; Patel, Chirag K.
CS School of Chemical and Pharmaceutical Sciences, Kingston University, Kingston upon Thames, Surrey, KT1 2EE, UK
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(10), 1343-1346
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB 4-(4-RC6H4)C6H4O3SNH2 [= H, CN, CO2Me, CO2Et, CO2Pr, CO2Bu] were prepd.as novel inhibitors of the enzyme estrone sulfatase (ES). The results of the study show that these compds. are potent inhibitors, possessing greater inhibitory activity than coumate, but weaker inhibitory activity than emate or the tricyclic deriv. of coumate, namely 667-coumate. Furthermore, the compds. are obsd. to be irreversible inhibitors.
IT **25999-01-3P 319014-71-6P 319014-72-7P**
471269-63-3P 471269-64-4P 471269-65-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and estrone sulfatase inhibiting activity of sulfamoyloxybiphenyls as steroid AC ring mimics)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 319014-72-7 CAPLUS
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:63493 CAPLUS
DN 136:112635
TI Biphenylyl sulfamates as steroid sulfatase inhibitors for estrogen-dependent diseases
IN Jinbo, Yoshikazu; Miyasaka, Tomohiro; Inoue, Yoshimasa
PA Japan Organo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002020362	A2	20020123	JP 2000-245314	20000706
PRAI JP 2000-245314		20000706		

OS MARPAT 136:112635
AB 4-RC6H4C6H4OSO2NH2-4 [I; R = CO2H, CONR1R2, CONR1OCH2Ph, COR2, C(OH)R1R2; R1 = H, (un)substituted alkyl; 2 = (un)substituted alkyl] are prepd. I are useful for treatment of mammary cancer, endometrial cancer, endometriosis, uterine myoma, etc. I (R = COCH2C6H4CMe3-4) (prepn. given) inhibited human placenta-derived steroid sulfatase at IC50 3.6 .mu.M.
IT **390358-08-4P 390358-09-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of biphenylyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)
RN 390358-08-4 CAPLUS
CN Sulfamic acid, 4'-acetyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-09-5 CAPLUS
CN Sulfamic acid, 4'-[[4-(1,1-dimethylethyl)phenyl]acetyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT **390358-11-9P 390358-12-0P 390358-14-2P**
390358-16-4P 390358-17-5P 390358-19-7P
390358-21-1P 390358-23-3P 390358-25-5P
390358-27-7P 390358-29-9P 390358-31-3P
390358-33-5P 390358-34-6P 390358-35-7P

390358-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biphenylyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)

RN 390358-11-9 CAPLUS
CN Sulfamic acid, 4'-(1-oxopentyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-12-0 CAPLUS
CN Sulfamic acid, 4'-(1-oxoheptyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-14-2 CAPLUS
CN Sulfamic acid, 4'-[(ethylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-16-4 CAPLUS
CN Sulfamic acid, 4'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-17-5 CAPLUS
CN Sulfamic acid, 4'-[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-19-7 CAPLUS
CN Sulfamic acid, 4'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-21-1 CAPLUS
CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-23-3 CAPLUS
CN Sulfamic acid, 4'-[[(phenylmethoxy)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-25-5 CAPLUS
CN Sulfamic acid, 4'-[[methyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-27-7 CAPLUS
CN Sulfamic acid, 4'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]methylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-29-9 CAPLUS
CN Sulfamic acid, 4'-[[butyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-31-3 CAPLUS
CN Sulfamic acid, 4'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]octylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-33-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 390358-34-6 CAPLUS
CN Sulfamic acid, 4'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-35-7 CAPLUS
CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxyethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-36-8 CAPLUS
CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxy-1-methylethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:453763 CAPLUS
DN 103:53763
TI Biphase systems. 7. Synthesis of simple and N-substituted sulfamates under conditions of liquid-liquid phase transfer
AU Hedayatullah, Mir; Hugueny, Jean Claude
CS Inst. Topol. Dyn. Syst., Univ. Paris VII, Paris, 75005, Fr.
SO Phosphorus and Sulfur and the Related Elements (1984), 20(3), 371-5
CODEN: PREEDF; ISSN: 0308-664X
DT Journal
LA French
AB Sulfamates p-R1C6H4OSO2NR2 (R2N = H2N, piperidino, morpholino, 1-pyrrolidinyl; R1 = H, Me, Cl, Ph) were prepd. by redn. of azides p-R1C6H4SO2N3 or by esterification of phenols p-R1C6H4OH with R2NSO2Cl under phase-transfer catalysis conditions.
IT **25999-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:442661 CAPLUS
DN 89:42661
TI A convenient synthesis of aryl sulfamates
AU Hedayatullah, Mir; Guy, Alain
CS Lab. Chim. Org., Conservatoire Natl. Arts Metiers, Paris, Fr.
SO Synthesis (1978), (5), 357
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
AB RnC6H5-nO3SNH2 (Rn = H, 2-, 4-Me, 2,6-Me2, 2-, 4-Ph, 4-Cl) were prepd. in 50-75% yield by NaBH4 redn. of RnC6H5-nO3SN3.
IT **25999-01-3P 67073-77-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 67073-77-2 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:547252 CAPLUS
DN 83:147252
TI Synthesis and reduction of aryl azidosulfates. VI
AU Hedayatullah, Mir; Guy, Alain
CS Lab. Chim. Org. Appl., Conservatoire Natl. Arts Metiers, Paris, Fr.
SO Tetrahedron Letters (1975), (29), 2455-8
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA French
AB Reaction of p-RC6H4OSO2Cl (R = H, Me, Cl, Ph) with NaN3 in MeCN gave 90-8% p-RC6H4OSO2N3 (I) which in MeOH with powd. Cu gave 47-86% p-RC6H4OSO2NH2. LiAlH4 redn. of I gave the corresponding phenols by cleavage of the O-S bond.
IT **25999-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1972:539511 CAPLUS
DN 77:139511
TI Preparation and reactions of aryloxysulfonyl isocyanates
AU Lohaus, Gerhard
CS Farbwerke Hoechst A.-G., Frankfurt/M., Fed. Rep. Ger.
SO Chemische Berichte (1972), 105(9), 2791-9
CODEN: CHBEAM; ISSN: 0009-2940
DT Journal
LA German
AB Re-action of phenols ROH (e.g. R = Ph, p-MeC6H4, m-ClC6H4, 2,4,6-Cl3C6H2, p-NCC6H4) with ClSO2NCO gave 40-79% ROSO2NCO (I). Hydrolysis of I yielded nearly quant. ROSO2NH2 (II). I are highly active compds. and the reactivity corresponded to the acidity of the starting phenols. II was useful for the transfer of SO2NH2 groups, e.g. to amines.
IT **25999-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1970:55051 CAPLUS
DN 72:55051
TI Sulfamic acid aryl esters
PA Farbwerke Hoechst A.-G
SO Fr., 3 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1554976		19690124		
PRAI	DE		19670128		

AB Isocyanates Ar(OSO2NCO)n (where Ar = aryl, n = 1 or 2) (Ger. 1,230,017) react with H2O to yield aryl sulfamate N-carboxylic acids which lose CO2 spontaneously to form Ar(OSO2NH2)n (I). Thus, 15 g H2O is added dropwise to 64 g 4-NCC6H4OSO2NCO in 500 ml CCl4 to ppt. 55 g 4-NCC6H4-OSO2NH2, m. 155.degree.. Other I (n = 1) prepd. are the following (Ar and m.p. given): 4-ClC6H4, 105.degree.; 3-ClC6H4, 80.degree.; Ph, 86.degree.; 4-MeC6H4, 80.degree.; 3-MeC6H4, 88.degree.; 2,6-Me2C6H3, 110.degree.; 2,3-Me2-C6H3, 78.degree.; 2,5-Me2C6H3, 104.degree.; 2,4,5-Cl3C6H2 (II), 158.degree.; 2,4,6-Cl3C6H2, 144.degree.; 2,4,6-Br3C6H2, 164.degree.; C6Cl5, 215.degree.; 4-MeO-C6H4, 165.degree.; 4-PhN2C6H4, 160.degree.; the sulfonate of 3-hydroxydibenzofuran, 156.degree.; and hydroquinone bis(sulfamate), 200.degree.. The compds. are useful for transferring the sulfonamide group. Thus, by shaking 1.35 g II with 0.9 g morpholine in 5 ml CH2Cl2, the ester dissolves to yield 0.71 g morpholine-N-sulfonamide, m. 160.degree..

IT **25999-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 17:19:24 ON 02 OCT 2003)

     FILE 'REGISTRY' ENTERED AT 17:19:37 ON 02 OCT 2003
L1             SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L2             STRUCTURE UPLOADED
L3             QUE L2 NOT L1
L4           2 S L3 SSS SAM
L5          63 S L3 SSS FUL

     FILE 'CAPLUS' ENTERED AT 17:20:32 ON 02 OCT 2003
L6          17 S L5

     FILE 'CAOLD' ENTERED AT 17:21:13 ON 02 OCT 2003

=> s l5
L7           0 L5

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.40     226.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -11.07

STN INTERNATIONAL LOGOFF AT 17:21:27 ON 02 OCT 2003
```

L6 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:31456 CAPLUS
DN 134:100645
TI Preparation of phenyl sulfamate derivatives as steroid sulfatase inhibitors
IN Koizumi, Naoyuki; Okada, Makoto; Iwashita, Shigeki; Takegawa, Shigehiro; Nakagawa, Takayoshi; Takahashi, Hiroo; Fujii, Tomohito
PA Teikoku Hormone Mfg. Co., Ltd., Japan
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002349	A1	20010111	WO 2000-JP4427	20000704
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2002293768	A2	20021009	JP 1999-191632	19990706
	EP 1193250	A1	20020403	EP 2000-940936	20000704
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	JP 1999-191632	A	19990706		
	WO 2000-JP4427	W	20000704		

OS MARPAT 134:100645
AB Ph sulfamate derivs. of general formula (I) or salts thereof [wherein R1, R2 = H, lower alkyl; R3 = H, halo, lower alkyl, OSO2NR1R2, lower alkanoylamino, NO2, cyano; A = (un)substituted Ph, naphthyl, pyridyl, 2-substituted thiazol-4-yl, 3-substituted-isoxazol-5-yl, 1-cyano-2-(optionally substituted phenyl)vinyl, 3-cyano-2-(optionally substituted phenyl)vinyl, X-NR4R5 (wherein X = CO, CH2; R4 = H, lower alkyl, optionally substituted Ph, lower alkanoyl, optionally substituted phenylcarbonyl, heteroarylcarbonyl, lower alkylsulfonyl, SO2NH2, etc.; R5 = H, optionally substituted Ph or phenylcarbonyl; provisos are given); or R3 and A together with Ph group to which they are bonded represent fluoren-2-yl or 9-oxofluoren-2-yl; provided that when R3 = H, A .noteq. unsubstituted Ph] are prepd. These compds. exhibit an excellent steroid sulfatase inhibitory activity and being therefore effective in the prevention or treatment of diseases related to steroids including estrogen, e.g., mammary carcinoma, carcinoma of uterine body, endometrial hyperplasia, sterility, endometriosis, adenomyosis of uterus, autoimmune diseases, dementia, Alzheimer's disease and so on. Thus, 108 mg 2'-biphenyl-4-ol was dissolved in DMF and stirred with under ice-cooling for 10 min, treated with 367 mg sulfamoyl chloride, and stirred at room temp. for 3 h to give 2'-nitrobiphenyl-4-yl sulfamate (II). II and 2'-cyano-4'-nitrobiphenyl-4-yl sulfamate at 0.5 mg/kg p.o. in rats inhibited steroid sulfatase by 91.2 and 99.5%, resp., in liver and 94.9 and 100%, resp., in uterus.
IT **319014-55-6P**, 2'-Nitrobiphenyl-4-yl sulfamate **319014-56-7P**, 4'-Hydroxy-2-cyanobiphenyl-4-yl sulfamate **319014-57-8P**, 2'-Fluorobiphenyl-4-yl sulfamate **319014-59-0P**, 2'-(Trifluoromethyl)biphenyl-4-yl sulfamate **319014-60-3P**, 2'-Methylbiphenyl-4-yl sulfamate **319014-61-4P**, Biphenyl-2,4'-diyl disulfamate **319014-62-5P**, 2'-Cyanomethylbiphenyl-4-yl sulfamate **319014-63-6P**, 3'-Fluorobiphenyl-4-yl sulfamate **319014-64-7P**, 3'-Nitrobiphenyl-4-yl sulfamate **319014-65-8P**,

3'-Cyanobiphenyl-4-yl sulfamate **319014-66-9P**,
3'-Cyanomethylbiphenyl-4-yl sulfamate **319014-67-0P**,
4'-Bromobiphenyl-4-yl sulfamate **319014-68-1P**,
4'-Chlorobiphenyl-4-yl sulfamate **319014-69-2P**,
4'-Methoxybiphenyl-4-yl sulfamate **319014-70-5P**,
4'-Nitrobiphenyl-4-yl sulfamate **319014-71-6P**, Methyl
4'-(sulfamoyloxy)-4-biphenylcarboxylate **319014-72-7P**,
4'-Cyanobiphenyl-4-yl sulfamate **319014-73-8P**,
4'-Trifluoromethylbiphenyl-4-yl sulfamate **319014-75-0P**,
4'-(Cyanomethyl)biphenyl-4-yl sulfamate **319014-76-1P**,
Biphenyl-4,4'-diyl disulfamate **319014-78-3P**,
2-Nitrobiphenyl-4,4'-diyl disulfamate **319014-79-4P**,
2',4'-Dinitrobiphenyl-4-yl sulfamate **319014-80-7P**,
2,2'-Dinitrobiphenyl-4,4'-diyl disulfamate **319014-81-8P**,
2'-Cyano-4'-nitrobiphenyl-4-yl sulfamate **319014-82-9P**,
4'-Cyano-2'-nitrobiphenyl-4-yl sulfamate **319014-83-0P**,
2',4'-Dicyanobiphenyl-4-yl sulfamate **319015-53-7P**
319015-61-7P, 3-Chlorobiphenyl-4-yl sulfamate **319015-62-8P**
, 3-Bromobiphenyl-4-yl sulfamate **319015-63-9P**,
3-Iodobiphenyl-4-yl sulfamate **319015-64-0P**, 3-
(Acetylamino)biphenyl-4-yl sulfamate **319015-66-2P**,
4'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate **319015-68-4P**,
2'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate **319015-70-8P**,
4'-(Methylsulfonyloxy)biphenyl-4-yl sulfamate **319015-80-0P**,
4'-(Sulfamoylamino)biphenyl-4-yl sulfamate **319015-81-1P**,
2'-(Sulfamoylamino)biphenyl-4-yl sulfamate **319015-86-6P**,
4'-Amino-2'-cyanobiphenyl-4-yl sulfamate **319015-87-7P**,
2'-Amino-4'-cyanobiphenyl-4-yl sulfamate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Ph sulfamate derivs. as steroid sulfatase inhibitors and drugs)

RN 319014-55-6 CAPLUS
CN Sulfamic acid, 2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-56-7 CAPLUS
CN Sulfamic acid, 2-cyano-4'-hydroxy[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-57-8 CAPLUS
CN Sulfamic acid, 2'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-59-0 CAPLUS
CN Sulfamic acid, 2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-60-3 CAPLUS
CN Sulfamic acid, 2'-methyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-61-4 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-2,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-62-5 CAPLUS
CN Sulfamic acid, 2'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-63-6 CAPLUS
CN Sulfamic acid, 3'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-64-7 CAPLUS
CN Sulfamic acid, 3'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-65-8 CAPLUS
CN Sulfamic acid, 3'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-66-9 CAPLUS
CN Sulfamic acid, 3'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-67-0 CAPLUS
CN Sulfamic acid, 4'-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-68-1 CAPLUS
CN Sulfamic acid, 4'-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-69-2 CAPLUS
CN Sulfamic acid, 4'-methoxy[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-70-5 CAPLUS
CN Sulfamic acid, 4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 319014-72-7 CAPLUS
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-73-8 CAPLUS
CN Sulfamic acid, 4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-75-0 CAPLUS
CN Sulfamic acid, 4'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-76-1 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-78-3 CAPLUS
CN Sulfamic acid, 2-nitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-79-4 CAPLUS
CN Sulfamic acid, 2',4'-dinitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-80-7 CAPLUS
CN Sulfamic acid, 2,2'-dinitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-81-8 CAPLUS
CN Sulfamic acid, 2'-cyano-4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-82-9 CAPLUS
CN Sulfamic acid, 4'-cyano-2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-83-0 CAPLUS
CN Sulfamic acid, 2',4'-dicyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-53-7 CAPLUS
CN Sulfamic acid, 4-(1-naphthalenyl)phenyl ester (9CI) (CA INDEX NAME)



RN 319015-61-7 CAPLUS
CN Sulfamic acid, 3-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-62-8 CAPLUS
CN Sulfamic acid, 3-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-63-9 CAPLUS
CN Sulfamic acid, 3-iodo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-64-0 CAPLUS
CN Sulfamic acid, 3-(acetylamino)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-66-2 CAPLUS
CN Sulfamic acid, 4'-[(methylsulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-68-4 CAPLUS
CN Sulfamic acid, 2'-[(methylsulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-70-8 CAPLUS
CN Sulfamic acid, 4'-[(methylsulfonyl)oxy][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-80-0 CAPLUS
CN Sulfamic acid, 4'-[(aminosulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-81-1 CAPLUS
CN Sulfamic acid, 2'-[(aminosulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-86-6 CAPLUS
CN Sulfamic acid, 4'-amino-2'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-87-7 CAPLUS
CN Sulfamic acid, 2'-amino-4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:169243 CAPLUS
DN 124:316749
TI N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IN Lee, Helen T.; Picard, Joseph A.; Sliskovic, Drago R.; Wierenga, Wendell
PA Warner-Lambert Company, USA
SO U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 62,515, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5491172	A	19960213	US 1994-223932	19940413
	IL 109431	A1	20010111	IL 1994-109431	19940426
	CA 2158268	AA	19941124	CA 1994-2158268	19940511
	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 72653	A2	19960528	HU 1995-2811	19940511
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	AT 178891	E	19990415	AT 1994-916734	19940511
	ES 2133163	T3	19990901	ES 1994-916734	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	SK 282790	B6	20021203	SK 1995-1396	19940511
	ZA 9403313	A	19951113	ZA 1994-3313	19940513
	US 5633287	A	19970527	US 1995-546967	19951023
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	B2	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		

OS MARPAT 124:316749
AB The present invention is directed to title ACAT-inhibiting compds. R1XSO2NRCOYR2 useful for the regulation of cholesterol, methods for using them and pharmaceutical compns. thereof, wherein: X and Y are oxygen, sulfur, or (CR'R'')n wherein n is 1 to 4 and R' and R'' are each independently, e.g., H, alkyl, alkoxy or R' and R'' together form a spirocycloalkyl or a carbonyl; R is hydrogen, alkyl, or benzyl; R1 and R2 are Ph, substituted Ph, naphthyl, substituted naphthyl, an aralkyl group, an alkyl chain, adamantyl, or a cycloalkyl group. Thus, e.g., hydroxyethylation of 2,6-diisopropylbromobenzene with Li/ethylene oxide afforded 2-(2,6-diisopropylphenyl)ethanol; Jones oxidn. of the latter afforded the (2,6-diisopropylphenyl)acetic acid; conversion to the acid chloride followed by amidation with 2,6-diisopropylphenyl sulfamate afforded ArCH2CONHSO2OAr (Ar = 2,6-diisopropylphenyl) which exhibited IC50 = 9.7 .mu.M for inhibition of ACAT in vitro and -63% change in mean cholesterol levels in vivo.
IT **166519-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(N-acyl sulfamic acid esters, N-acyl sulfonamides, and N-sulfonyl carbamic acid esters as hypercholesterolemic agents)

RN 166519-18-2 CAPLUS

CN Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:742595 CAPLUS
DN 123:143436
TI N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IN Lee, Helen Tsenwhei; Picard, Joseph Armand; Sliskovic, Drago Robert; Wierenga, Wendell
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5491172	A	19960213	US 1994-223932	19940413
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	SK 282790	B6	20021203	SK 1995-1396	19940511
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	A	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		

OS MARPAT 123:143436
AB Compds. of formula R1XS(O2)NRCOYR2 (R = H, C1-8 alkyl, benzyl; R1, R2 = Ph, phenoxy, naphthyl, arylalkyl, C1-20 alkyl, etc.; X, Y = O, S, alkyl), or their salts, are useful for the regulation of plasma cholesterol. Compds. may be used for treatment of hypercholesterolemia and atherosclerosis. Prepn. of 48 compds. is presented.
IT **166519-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of acyl sulfamic acid esters (or thioesters), acyl sulfonamides, and sulfonyl carbamic acid esters (or thioesters) as antihypercholesterolemic agents)
RN 166519-18-2 CAPLUS
CN Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1963:421587 CAPLUS
DN 59:21587
OREF 59:3853b,3854a
TI Aromatic carboxylic acids
IN Juettner, Bernhard; Bennin, Anton
PA Bergwerksverband G.m.b.H.
SO 4 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1136687		19620920	DE	19610420

AB Aromatic alkyl compds. were oxidized in aq. lye with Cl in the presence of at least 50 wt.-% (calcd. on the aromatic alkyl compd.) of a Mn salt or MnO2 to give white, Cl-free aromatic carboxylic acids; the MnO2 can be re-used. Thus, Cl 55 passed within 2 hrs. into a boiling mixt. of H2O 700, NaOH 80, MnSO4 7 and p-MeC5H4CO2H 13.6, after 2 hrs. the whole cooled, the MnO2 (hydrate) filtered off, and the colorless filtrate carefully acidified (H2SO4) gave Cl-free p-C6H4(CO2H)2 (I) 14.8; using MnO2 2 wt. parts gave an oxidn. product contg. 2.1% Cl. A mixt. 12.2 of 60% p- and 40% o-MeC6H4CH2OH oxidized similarly gave I 8.5 and (by extn. of the filtrate) o-C6H4(CO2H)2 (II) 5.8 wt. parts; a mixt. of the same cmnpds. (obtained by boiling 1 hr. a mixt. of 57% p- and 43% o-ClCH2C6H4Me 14 with NaOH 40 in H2O 1000) gave I 8 and II 4 wt. parts. Also prepd. were I, pyromellitic acid, and light-yellow a-naphthoic acid (crystd. several times from 30% MeOH) from p-xylene, durene, and a-methylnaphthalene, resp.

IT **101547-37-9**, Sulfamic acid, dipropyl-, 4,4'-biphenylylene ester (prepn. of)
RN 101547-37-9 CAPLUS
CN Sulfamic acid, dipropyl-, 4,4'-biphenylylene ester (7CI) (CA INDEX NAME)



1026

L12 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1963:421586 CAPLUS
DN 59:21586
OREF 59:3852g-h,3853a-b
TI Aryl dialkylsulfamates
IN Dunbar, Joseph E.
PA to Dow Chemical Co.
SO 4 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3082238		19630319	US	19600328

AB The title compds. (I) have the formula Ar(OSO2NR2)n. I are useful as aquatic and terrestrial herbicides in the control of Anacharns, Lysimiachia nummularia, Salvinia rotundifolia and beratophyllum and as foliage fungicides in the control of late blight, wheat leaf rust and, cucumber powdery mildew. I are prepd. by the reaction of a phenol, Ar(OH)n with a dialkylsulfamoyl chloride R2NSO2Cl in a basic reaction medium. In an example, 15.1 g. dimethylsulfamoyl chloride was added to a stirred soln. of 20.8 g. 2,4,5-trichlorophenol in 50 ml. NEt3 at 62.degree.. The mixt. was stirred 4 hrs. while cooling to room temp., then poured into a mixt. of ice and concd. HCl to yield an oil which crystd. on standing. The sepd. solid was washed with H2O, 10% NaOH soln., and H2O to yield 2,4,5-trichlorophenyl dimethylsulfamate (II), m. 66-7.degree. (aq. EtOH). II was also prepd. using NaOH in place of NEt3. Also prepd. were: pentachlorophenyl dimethylsulfamate, m. 150-1.degree. (EtOH); 4-tert-butyl-2-chlorophenyl dimethylsulfamate, m. 36-7.degree. (EtOH); 4-nitrephenyl dimethylsulfamate, m. 123.5-4.5.degree. (EtOH); 3,5-dimethyl-4-dimethylaminophenyl dimethylsulfamate, m. 28- 9.degree. (aq. EtOH); 1-naphthyl dimethylsulfamate, m. 76-7.degree. (aq. MeOH); 2-naphthyl dimethylsulfamate, m. 72-3.degree. (EtOH); 4,4'-biphenylyl bis(dimethylsulfaniate), m. 191-2.degree. (HOAc); 2-methyl-4-isopropylphenyl diethylsulfamate; 2-nitro-4-tert-butylphenyl diethylsulfamate; 4-diethylaminophenyl dibutylsulfamate, and 4,4'-biphenylyl bis(dipropylsulfamate).

IT **98176-69-3**, Sulfamic acid, dimethyl-, 4,4'-biphenylylene ester (prepn. of)
RN 98176-69-3 CAPLUS
CN Sulfamic acid, dimethyl-, 4,4'-biphenylylene ester (7CI) (CA INDEX NAME)



L12 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1981:586905 CAPLUS
DN 95:186905
TI Herbicidal benzamides
PA Hodogaya Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56083467	A2	19810708	JP 1979-159270	19791210
	JP 62023748	B4	19870525		
PRAI	JP 1979-159270		19791210		

AB Herbicidal benzamides I (R = halo- or alkyl-substituted alkylsulfonyloxy, alkylsulfamoyloxy) were prepd. Thus, stirring the K salt of I (R = OH) with MeSO2Cl in acetone 6 h gave 86.3% I (R = MeSO3).

IT **79603-69-3P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and herbicidal activity of)

RN 79603-69-3 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[[(2,3-dichlorophenyl)amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



10 (b)

L12 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1963:421587 CAPLUS
DN 59:21587
OREF 59:3853b,3854a
TI Aromatic carboxylic acids
IN Juettner, Bernhard; Bennin, Anton
PA Bergwerksverband G.m.b.H.
SO 4 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1136687		19620920	DE	19610420

AB Aromatic alkyl compds. were oxidized in aq. lye with Cl in the presence of at least 50 wt.-% (calcd. on the aromatic alkyl compd.) of a Mn salt or MnO2 to give white, Cl-free aromatic carboxylic acids; the MnO2 can be re-used. Thus, Cl 55 passed within 2 hrs. into a boiling mixt. of H2O 700, NaOH 80, MnSO4 7 and p-MeC5H4CO2H 13.6, after 2 hrs. the whole cooled, the MnO2 (hydrate) filtered off, and the colorless filtrate carefully acidified (H2SO4) gave Cl-free p-C6H4(CO2H)2 (I) 14.8; using MnO2 2 wt. parts gave an oxidn. product contg. 2.1% Cl. A mixt. 12.2 of 60% p- and 40% o-MeC6H4CH2OH oxidized similarly gave I 8.5 and (by extn. of the filtrate) o-C6H4(CO2H)2 (II) 5.8 wt. parts; a mixt. of the same cmnpds. (obtained by boiling 1 hr. a mixt. of 57% p- and 43% o-ClCH2C6H4Me 14 with NaOH 40 in H2O 1000) gave I 8 and II 4 wt. parts. Also prepd. were I, pyromellitic acid, and light-yellow a-naphthoic acid (crystd. several times from 30% MeOH) from p-xylene, durene, and a-methylnaphthalene, resp.

IT **101547-37-9**, Sulfamic acid, dipropyl-, 4,4'-biphenylylene ester (prepn. of)
RN 101547-37-9 CAPLUS
CN Sulfamic acid, dipropyl-, 4,4'-biphenylylene ester (7CI) (CA INDEX NAME)



1026

L12 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1963:421586 CAPLUS
DN 59:21586
OREF 59:3852g-h,3853a-b
TI Aryl dialkylsulfamates
IN Dunbar, Joseph E.
PA to Dow Chemical Co.
SO 4 pp.
DT Patent
LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3082238		19630319	US	19600328

AB The title compds. (I) have the formula Ar(OSO2NR2)n. I are useful as aquatic and terrestrial herbicides in the control of Anacharns, Lysimiachia nummularia, Salvinia rotundifolia and beratophyllum and as foliage fungicides in the control of late blight, wheat leaf rust and, cucumber powdery mildew. I are prepd. by the reaction of a phenol, Ar(OH)n with a dialkylsulfamoyl chloride R2NSO2Cl in a basic reaction medium. In an example, 15.1 g. dimethylsulfamoyl chloride was added to a stirred soln. of 20.8 g. 2,4,5-trichlorophenol in 50 ml. NEt3 at 62.degree.. The mixt. was stirred 4 hrs. while cooling to room temp., then poured into a mixt. of ice and concd. HCl to yield an oil which crystd. on standing. The sepd. solid was washed with H2O, 10% NaOH soln., and H2O to yield 2,4,5-trichlorophenyl dimethylsulfamate (II), m. 66-7.degree. (aq. EtOH). II was also prepd. using NaOH in place of NEt3. Also prepd. were: pentachlorophenyl dimethylsulfamate, m. 150-1.degree. (EtOH); 4-tert-butyl-2-chlorophenyl dimethylsulfamate, m. 36-7.degree. (EtOH); 4-nitrephenyl dimethylsulfamate, m. 123.5-4.5.degree. (EtOH); 3,5-dimethyl-4-dimethylaminophenyl dimethylsulfamate, m. 28- 9.degree. (aq. EtOH); 1-naphthyl dimethylsulfamate, m. 76-7.degree. (aq. MeOH); 2-naphthyl dimethylsulfamate, m. 72-3.degree. (EtOH); 4,4'-biphenylyl bis(dimethylsulfaniate), m. 191-2.degree. (HOAc); 2-methyl-4-isopropylphenyl diethylsulfamate; 2-nitro-4-tert-butylphenyl diethylsulfamate; 4-diethylaminophenyl dibutylsulfamate, and 4,4'-biphenylyl bis(dipropylsulfamate).

IT **98176-69-3**, Sulfamic acid, dimethyl-, 4,4'-biphenylylene ester (prepn. of)

RN 98176-69-3 CAPLUS
CN Sulfamic acid, dimethyl-, 4,4'-biphenylylene ester (7CI) (CA INDEX NAME)



L12 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1981:586905 CAPLUS
DN 95:186905
TI Herbicidal benzamides
PA Hodogaya Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56083467	A2	19810708	JP 1979-159270	19791210
	JP 62023748	B4	19870525		
PRAI	JP 1979-159270		19791210		

AB Herbicidal benzamides I (R = halo- or alkyl-substituted alkylsulfonyloxy, alkylsulfamoyloxy) were prepd. Thus, stirring the K salt of I (R = OH) with MeSO2Cl in acetone 6 h gave 86.3% I (R = MeSO3).

IT **79603-69-3P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and herbicidal activity of)

RN 79603-69-3 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[[(2,3-dichlorophenyl)amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1993:101936 CAPLUS
DN 118:101936
TI Preparation of 2-phenyloxazoline compounds as herbicides
IN Sato, Kazuo; Kudo, Noriaki; Honma, Toyokuni; Endo, Takeshi; Shindo, Masahiro
PA Sankyo Co., Ltd., Japan
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9212139	A1	19920723	WO 1991-JP1767	19911226
	W: AU, CA, HU, KR, PL, RO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	JP 05170750	A2	19930709	JP 1991-340761	19911224
	JP 3294627	B2	20020624		
	AU 9191075	A1	19920817	AU 1991-91075	19911226
PRAI	JP 1990-407871	A	19901227		
	JP 1991-279671	A	19911025		
	WO 1991-JP1767	A	19911226		

OS MARPAT 118:101936
AB The title compds. [I; R1 = lower alkyl; R2 = lower (halo)alkyl; R3 = H, lower alkyl, QR4 where Q = O or S ; R4 = H, lower alkyl, cycloalkyl, lower alkenyl, lower alkynyl, acyl, lower alkoxycarbonyl, aryloxycarbonyl, CONH2, SONH2, lower alkylsulfonyl, arylsulfonyl, di(lower alkoxy)(thio)phosphoryl, tri(lower alkyl)silyl, 5- or 6-membered satd. heterocyclyl contg. 1-3 same or different heteroatoms selected form O, S, and N; wherein R4 may be substituted; W = O, S; X = H, halo, lower alkyl, lower alkylthio; Y, Z = H, halo, lower alkyl, cyano] are prepd. Thus, 24.6 mL of a soln. of 1 M (Me3Si)2Li in THF was slowly added to a soln. of 3.59 g Et N-[4-chloro-2-fluoro-5-(2-methoxyethoxymethoxy)phenyl]carbamate and 2.60 g 1-bromo-3,3-dimethyl-2-butane in DMF at room temp. and the mixt. was stirred for 30 min, poured into H2O, and extd. with EtOAc to give, after silica gel chromatog., 48.4% I (R1 = R2 = Me, R3 = OCH2CH2CH2OMe, X = H, Y = F, Z = Cl, W = O). This at 5 g/are controlled 91-100% Echinochloa crus-galli and Monochoria vaginalis without inflicting injury to rice seedlings. A total of 253 I were prepd.
IT **145859-49-0P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide)
RN 145859-49-0 CAPLUS
CN Sulfamic acid, dimethyl-, 2-chloro-5-[4-chloro-5-(1,1-dimethylethyl)-2-oxo-3(2H)-oxazolyl]-4-fluorophenyl ester (9CI) (CA INDEX NAME)


Me2N
S
O
Cl
F
N
Cl
Bu-t

L12 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1979:54664 CAPLUS
DN 90:54664
TI Substituted 2-aminomethylphenyl sulfamates
IN Smith, Robert L.; Stokker, Gerald E.; Cragoe, Edward J., Jr.
PA Merck and Co., Inc., USA
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4113877	A	19780912	US 1977-833930	19770916
DK 7804086	A	19790317	DK 1978-4086	19780915
EP 1266	A1	19790404	EP 1978-100901	19780915
EP 1266	B1	19810401		
R: BE, CH, DE, FR, GB, LU, NL, SE				
JP 54052056	A2	19790424	JP 1978-114022	19780916
PRAI US 1977-833930		19770916		

AB Title esters I (R = the same or different alkyl, alkoxy, aralkyl, Ph or halo; R1, R2 = H, C1-5 alkyl, Ph or aralkyl; n = 0-4), useful as diuretics or saluretics (no data), were prepd. by treating N-blocked 2-(aminomethyl)phenols with sulfamoyl chlorides followed by deblocking the products. Thus, 2-(aminomethyl)-4-tert-butyl-6-iodophenol was blocked by treatment with (CF3CO)2O, esterified with Me2NSO2Cl, and deblocked to give I (Rn = 4-tert-Bu, 6-iodo, R1 = R2 = Me) as the hydrochloride.

IT **68967-69-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)

RN 68967-69-1 CAPLUS
CN Sulfamic acid, dimethyl-, 4-(1,1-dimethylethyl)-2-iodo-6-[[(trifluoroacetyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



IT **68967-66-8P 68967-71-5P 68967-73-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and decarboxylation of)

RN 68967-66-8 CAPLUS
CN Carbamic acid, [[2-[[(dimethylamino)sulfonyl]oxy]-5-(1,1-dimethylethyl)-3-iodophenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 68967-71-5 CAPLUS
CN Carbamic acid, [[3-chloro-2-[[(dimethylamino)sulfonyl]oxy]-5-(1,1-dimethylethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 68967-73-7 CAPLUS
CN Carbamic acid, [[5-(1,1-dimethylethyl)-2-[[(ethylamino)sulfonyl]oxy]-3-iodophenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **68967-67-9P 68967-72-6P 68967-74-8P**
68967-76-0P 68967-77-1P 68967-78-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 68967-67-9 CAPLUS
CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 68967-72-6 CAPLUS
CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-6-chloro-4-(1,1-dimethylethyl)phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 68967-74-8 CAPLUS
CN Sulfamic acid, ethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 68967-76-0 CAPLUS
CN Sulfamic acid, (1,1-dimethylethyl)-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 68967-77-1 CAPLUS
CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester (9CI) (CA INDEX NAME)



RN 68967-78-2 CAPLUS
CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L12 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2001:31456 CAPLUS
DN 134:100645
TI Preparation of phenyl sulfamate derivatives as steroid sulfatase inhibitors
IN Koizumi, Naoyuki; Okada, Makoto; Iwashita, Shigeki; Takegawa, Shigehiro; Nakagawa, Takayoshi; Takahashi, Hiroo; Fujii, Tomohito
PA Teikoku Hormone Mfg. Co., Ltd., Japan
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002349	A1	20010111	WO 2000-JP4427	20000704
W: AU, CA, CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2002293768	A2	20021009	JP 1999-191632	19990706
EP 1193250	A1	20020403	EP 2000-940936	20000704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI JP 1999-191632	A	19990706		
WO 2000-JP4427	W	20000704		

OS MARPAT 134:100645
AB Ph sulfamate derivs. of general formula (I) or salts thereof [wherein R1, R2 = H, lower alkyl; R3 = H, halo, lower alkyl, OSO2NR1R2, lower alkanoylamino, NO2, cyano; A = (un)substituted Ph, naphthyl, pyridyl, 2-substituted thiazol-4-yl, 3-substituted-isoxazol-5-yl, 1-cyano-2-(optionally substituted phenyl)vinyl, 3-cyano-2-(optionally substituted phenyl)vinyl, X-NR4R5 (wherein X = CO, CH2; R4 = H, lower alkyl, optionally substituted Ph, lower alkanoyl, optionally substituted phenylcarbonyl, heteroarylcarbonyl, lower alkylsulfonyl, SO2NH2, etc.; R5 = H, optionally substituted Ph or phenylcarbonyl; provisos are given); or R3 and A together with Ph group to which they are bonded represent fluoren-2-yl or 9-oxofluoren-2-yl; provided that when R3 = H, A .noteq. unsubstituted Ph] are prepd. These compds. exhibit an excellent steroid sulfatase inhibitory activity and being therefore effective in the prevention or treatment of diseases related to steroids including estrogen, e.g., mammary carcinoma, carcinoma of uterine body, endometrial hyperplasia, sterility, endometriosis, adenomyosis of uterus, autoimmune diseases, dementia, Alzheimer's disease and so on. Thus, 108 mg 2'-biphenyl-4-ol was dissolved in DMF and stirred with under ice-cooling for 10 min, treated with 367 mg sulfamoyl chloride, and stirred at room temp. for 3 h to give 2'-nitrobiphenyl-4-yl sulfamate (II). II and 2'-cyano-4'-nitrobiphenyl-4-yl sulfamate at 0.5 mg/kg p.o. in rats inhibited steroid sulfatase by 91.2 and 99.5%, resp., in liver and 94.9 and 100%, resp., in uterus.
IT **319014-55-6P**, 2'-Nitrobiphenyl-4-yl sulfamate **319014-56-7P**, 4'-Hydroxy-2-cyanobiphenyl-4-yl sulfamate **319014-57-8P**, 2'-Fluorobiphenyl-4-yl sulfamate **319014-59-0P**, 2'-(Trifluoromethyl)biphenyl-4-yl sulfamate **319014-60-3P**, 2'-Methylbiphenyl-4-yl sulfamate **319014-61-4P**, Biphenyl-2,4'-diyl disulfamate **319014-62-5P**, 2'-Cyanomethylbiphenyl-4-yl sulfamate **319014-63-6P**, 3'-Fluorobiphenyl-4-yl sulfamate **319014-64-7P**, 3'-Nitrobiphenyl-4-yl sulfamate **319014-65-8P**,

3'-Cyanobiphenyl-4-yl sulfamate **319014-66-9P**,
3'-Cyanomethylbiphenyl-4-yl sulfamate **319014-67-0P**,
4'-Bromobiphenyl-4-yl sulfamate **319014-68-1P**,
4'-Chlorobiphenyl-4-yl sulfamate **319014-69-2P**,
4'-Methoxybiphenyl-4-yl sulfamate **319014-70-5P**,
4'-Nitrobiphenyl-4-yl sulfamate **319014-71-6P**, Methyl
4'-(sulfamoyloxy)-4-biphenylcarboxylate **319014-72-7P**,
4'-Cyanobiphenyl-4-yl sulfamate **319014-73-8P**,
4'-Trifluoromethylbiphenyl-4-yl sulfamate **319014-75-0P**,
4'-(Cyanomethyl)biphenyl-4-yl sulfamate **319014-76-1P**,
Biphenyl-4,4'-diyl disulfamate **319014-78-3P**,
2-Nitrobiphenyl-4,4'-diyl disulfamate **319014-79-4P**,
2',4'-Dinitrobiphenyl-4-yl sulfamate **319014-80-7P**,
2,2'-Dinitrobiphenyl-4,4'-diyl disulfamate **319014-81-8P**,
2'-Cyano-4'-nitrobiphenyl-4-yl sulfamate **319014-82-9P**,
4'-Cyano-2'-nitrobiphenyl-4-yl sulfamate **319014-83-0P**,
2',4'-Dicyanobiphenyl-4-yl sulfamate **319014-84-1P**,
[4-[N-Sulfamoyl-N-(4-(sulfamoyloxy)benzyl)amino]phenyl] sulfamate **319014-85-2P**, [4-[N-(Methylsulfonyl)-N-(4-(sulfamoyloxy)benzyl)amino]phenyl] sulfamate **319014-86-3P**,
[4-[N-Acetyl-N-(4-(sulfamoyloxy)benzyl)amino]phenyl] sulfamate **319014-87-4P**, [4-[N-Acetyl-N-(4-(sulfamoyloxy)benzyl)amino]phenyl] acetate **319014-88-5P**, [4-[N-(4-(Sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate **319014-89-6P**, [4-[N-Ethyl-N-(4-(sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate **319014-90-9P**,
[4-[N-Methyl-N-(4-(sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate **319014-91-0P**, [4-[N-(3-(Sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate **319014-92-1P**, [4-[N-Methyl-N-(3-(sulfamoyloxy)phenyl)carbamoyl]phenyl] sulfamate **319014-93-2P** **319014-95-4P** **319014-97-6P** **319014-99-8P**,
4-(N-Phenylaminomethyl)phenyl sulfamate **319015-00-4P**,
4-[N-(4-Cyanophenyl)aminomethyl]phenyl sulfamate **319015-01-5P**,
4-[N-(2-Cyanophenyl)aminomethyl]phenyl sulfamate **319015-02-6P**,
4-[N-(4-Hydroxyphenyl)aminomethyl]phenyl sulfamate **319015-03-7P**,
4-[N-(4-Nitrophenyl)aminomethyl]phenyl sulfamate **319015-04-8P** **319015-05-9P** **319015-06-0P**, 4-[[N,N-Bis(4-cyanophenyl)amino]methyl]phenyl sulfamate **319015-07-1P** **319015-08-2P**, 4-[[N-Phenyl-N-(sulfamoyl)amino]methyl]phenyl sulfamate **319015-09-3P**, 4-[[N-(4-Cyanophenyl)-N-(sulfamoyl)amino]methyl]phenyl sulfamate **319015-10-6P**,
4-[[N-(4-Cyanophenyl)-N-nicotinoylamino]methyl]phenyl sulfamate **319015-11-7P**, 4-[[N-Benzoyl-N-(4-cyanophenyl)amino]methyl]phenyl sulfamate **319015-12-8P**, 4-[[N-(4-Cyanobenzoyl)-N-(4-cyanophenyl)amino]methyl]phenyl sulfamate **319015-13-9P**,
4-(N,N-Diphenylcarbamoyl)phenyl sulfamate **319015-14-0P**,
4-(N-Benzylcarbamoyl)phenyl sulfamate **319015-15-1P**,
4-(N-Phenylcarbamoyl)phenyl sulfamate **319015-16-2P**,
4-[[N-(4-Cyanobenzoyl)-N-methylamino]methyl]phenyl sulfamate **319015-17-3P**, 4-[[N-(4H-1,2,4-Triazol-4-yl)amino]methyl]phenyl sulfamate **319015-18-4P**, 4-[[N-(3-Cyanobenzoyl)-N-(4H-1,2,4-triazol-4-yl)amino]methyl]phenyl sulfamate **319015-19-5P**,
4-[[N-(4-Cyanophenyl)-N-(3-pyridyl)amino]methyl]phenyl sulfamate **319015-23-1P**, 4-[[N-(4-Cyanophenyl)-N-methylamino]methyl]phenyl sulfamate **319015-26-4P**, 4-[[N-(4-Cyanophenyl)-N-ethylamino]methyl]phenyl sulfamate **319015-30-0P**,
4-[[N-(4-Cyanophenyl)-N-(2-thienylcarbonyl)amino]methyl]phenyl sulfamate **319015-34-4P**, 4-[[N-(4-Cyanophenyl)-N-(3-thienylcarbonyl)amino]methyl]phenyl sulfamate **319015-36-6P**,

4-[N-(4-Cyanophenyl)carbamoyl]phenyl sulfamate **319015-38-8P**, 4-[N-(4-Cyanophenyl)-N-methylcarbamoyl]phenyl sulfamate **319015-39-9P**, 4-(N',N'-Dimethylhydrazinocarbonyl)phenyl sulfamate **319015-40-2P**, 2-[N-(4-(Sulfamoyloxy)phenyl)carbamoyl]phenyl sulfamate **319015-42-4P**, 3-[N-(2-(Sulfamoyloxy)phenyl)carbamoyl]phenyl sulfamate **319015-43-5P**, 3-[N-(3-(Sulfamoyloxy)phenyl)carbamoyl]phenyl sulfamate **319015-45-7P**, 3-[N-(4-(Sulfamoyloxy)phenyl)carbamoyl]phenyl sulfamate **319015-46-8P**, 4-[N-(2-(Sulfamoyloxy)phenyl)carbamoyl]phenyl sulfamate **319015-48-0P**, 4-[[N-(4-Cyanophenyl)-N-(2-pyrazinyl)amino]methyl]phenyl sulfamate **319015-50-4P** **319015-52-6P** **319015-53-7P** **319015-54-8P**, 9-Oxofluoren-2-yl sulfamate **319015-55-9P**, Fluoren-2-yl sulfamate **319015-56-0P**, 4-(3-Pyridyl)phenyl sulfamate **319015-57-1P**, 4-(2-Methylthiazol-4-yl)phenyl sulfamate **319015-58-2P**, 4-(2-(Sulfamoyloxy)thiazol-4-yl)phenyl sulfamate **319015-60-6P**, 4-[3-(N-Methylcarbamoyl)isoxazol-5-yl]phenyl sulfamate **319015-61-7P**, 3-Chlorobiphenyl-4-yl sulfamate **319015-62-8P**, 3-Bromobiphenyl-4-yl sulfamate **319015-63-9P**, 3-Iodobiphenyl-4-yl sulfamate **319015-64-0P**, 3-(Acetylamino)biphenyl-4-yl sulfamate **319015-66-2P**, 4'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate **319015-68-4P**, 2'-((Methylsulfonyl)amino)biphenyl-4-yl sulfamate **319015-70-8P**, 4'-(Methylsulfonyloxy)biphenyl-4-yl sulfamate **319015-72-0P** **319015-74-2P** **319015-76-4P** **319015-78-6P**, 4-[[N-(4-Cyanophenyl)-N-(2-pyrimidinyl)amino]methyl]phenyl sulfamate **319015-79-7P**, 2'-Cyano-4'-nitrobiphenyl-4-yl N,N-dimethylsulfamate **319015-80-0P**, 4'-(Sulfamoylamino)biphenyl-4-yl sulfamate **319015-81-1P**, 2'-(Sulfamoylamino)biphenyl-4-yl sulfamate **319015-83-3P** **319015-85-5P** **319015-86-6P**, 4'-Amino-2'-cyanobiphenyl-4-yl sulfamate **319015-87-7P**, 2'-Amino-4'-cyanobiphenyl-4-yl sulfamate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of Ph sulfamate derivs. as steroid sulfatase inhibitors and drugs)

RN 319014-55-6 CAPLUS

CN Sulfamic acid, 2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-56-7 CAPLUS

CN Sulfamic acid, 2-cyano-4'-hydroxy[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-57-8 CAPLUS
CN Sulfamic acid, 2'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-59-0 CAPLUS
CN Sulfamic acid, 2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-60-3 CAPLUS
CN Sulfamic acid, 2'-methyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-61-4 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-2,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-62-5 CAPLUS
CN Sulfamic acid, 2'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-63-6 CAPLUS
CN Sulfamic acid, 3'-fluoro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-64-7 CAPLUS
CN Sulfamic acid, 3'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-65-8 CAPLUS
CN Sulfamic acid, 3'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-66-9 CAPLUS
CN Sulfamic acid, 3'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-67-0 CAPLUS
CN Sulfamic acid, 4'-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-68-1 CAPLUS
CN Sulfamic acid, 4'-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-69-2 CAPLUS
CN Sulfamic acid, 4'-methoxy[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-70-5 CAPLUS
CN Sulfamic acid, 4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 319014-72-7 CAPLUS
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-73-8 CAPLUS
CN Sulfamic acid, 4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-75-0 CAPLUS
CN Sulfamic acid, 4'-(cyanomethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-76-1 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-78-3 CAPLUS
CN Sulfamic acid, 2-nitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-79-4 CAPLUS
CN Sulfamic acid, 2',4'-dinitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-80-7 CAPLUS
CN Sulfamic acid, 2,2'-dinitro[1,1'-biphenyl]-4,4'-diyl ester (9CI) (CA INDEX NAME)



RN 319014-81-8 CAPLUS
CN Sulfamic acid, 2'-cyano-4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-82-9 CAPLUS
CN Sulfamic acid, 4'-cyano-2'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-83-0 CAPLUS
CN Sulfamic acid, 2',4'-dicyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-84-1 CAPLUS
CN Sulfamic acid, 4-[[(aminosulfonyl)[4-[(aminosulfonyl)oxy]phenyl]amino]meth

yl]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-85-2 CAPLUS
CN Sulfamic acid, 4-[[[4-[(aminosulfonyl)oxy]phenyl]methyl](methylsulfonyl)amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-86-3 CAPLUS
CN Sulfamic acid, 4-[acetyl[[4-[(aminosulfonyl)oxy]phenyl]methyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-87-4 CAPLUS
CN Sulfamic acid, 4-[[acetyl[4-(acetyloxy)phenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-88-5 CAPLUS
CN Sulfamic acid, 4-[[4-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-89-6 CAPLUS
CN Sulfamic acid, 4-[[4-[(aminosulfonyl)oxy]benzoyl]ethylamino]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-90-9 CAPLUS
CN Sulfamic acid, 4-[[4-[(aminosulfonyl)oxy]benzoyl]methylamino]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-91-0 CAPLUS
CN Sulfamic acid, 3-[[4-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-92-1 CAPLUS
CN Sulfamic acid, 3-[[4-[(aminosulfonyl)oxy]benzoyl]methylamino]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-93-2 CAPLUS
CN Benzoic acid, 4-[(aminosulfonyl)oxy]-, 2-acetyl-1-phenylhydrazide (9CI) (CA INDEX NAME)



RN 319014-95-4 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)-4H-1,2,4-triazol-4-ylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-97-6 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)-4H-1,2,4-triazol-4-ylamino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319014-99-8 CAPLUS
CN Sulfamic acid, 4-[(phenylamino)methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-00-4 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-01-5 CAPLUS
CN Sulfamic acid, 4-[[(2-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-02-6 CAPLUS
CN Sulfamic acid, 4-[[(4-hydroxyphenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-03-7 CAPLUS
CN Sulfamic acid, 4-[[(4-nitrophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-04-8 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)(4-methoxyphenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-05-9 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)phenylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-06-0 CAPLUS
CN Sulfamic acid, 4-[[bis(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-07-1 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)-4-pyridinylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-08-2 CAPLUS
CN Sulfamic acid, 4-[[(aminosulfonyl)phenylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-09-3 CAPLUS
CN Sulfamic acid, 4-[[(aminosulfonyl)(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-10-6 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)(3-pyridinylcarbonyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-11-7 CAPLUS
CN Sulfamic acid, 4-[[benzoyl(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-12-8 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanobenzoyl)(4-cyanophenyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-13-9 CAPLUS
CN Sulfamic acid, 4-[(diphenylamino)carbonyl]phenyl ester (9CI) (CA INDEX

NAME)



RN 319015-14-0 CAPLUS
CN Sulfamic acid, 4-[[(phenylmethyl)amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-15-1 CAPLUS
CN Sulfamic acid, 4-[(phenylamino)carbonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-16-2 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanobenzoyl)methylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-17-3 CAPLUS
CN Sulfamic acid, 4-[(4H-1,2,4-triazol-4-ylamino)methyl]phenyl ester (9CI)

(CA INDEX NAME)



RN 319015-18-4 CAPLUS
CN Sulfamic acid, 4-[[(3-cyanobenzoyl)-4H-1,2,4-triazol-4-ylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-19-5 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)-3-pyridinylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-23-1 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)methylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-26-4 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)ethylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-30-0 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)(2-thienylcarbonyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-34-4 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)(3-thienylcarbonyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-36-6 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)amino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-38-8 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)methylamino]carbonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-39-9 CAPLUS
CN Benzoic acid, 4-[(aminosulfonyl)oxy]-, 2,2-dimethylhydrazide (9CI) (CA INDEX NAME)



RN 319015-40-2 CAPLUS
CN Sulfamic acid, 4-[[2-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-42-4 CAPLUS
CN Sulfamic acid, 2-[[3-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-43-5 CAPLUS
CN Sulfamic acid, 3-[[3-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-45-7 CAPLUS
CN Sulfamic acid, 4-[[3-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI)

(CA INDEX NAME)



RN 319015-46-8 CAPLUS
CN Sulfamic acid, 2-[[4-[(aminosulfonyl)oxy]benzoyl]amino]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-48-0 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)pyrazinylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-50-4 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)(2-thienylmethyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-52-6 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)(3-thienylmethyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-53-7 CAPLUS
CN Sulfamic acid, 4-(1-naphthalenyl)phenyl ester (9CI) (CA INDEX NAME)



RN 319015-54-8 CAPLUS
CN Sulfamic acid, 9-oxo-9H-fluoren-2-yl ester (9CI) (CA INDEX NAME)



RN 319015-55-9 CAPLUS
CN Sulfamic acid, 9H-fluoren-2-yl ester (9CI) (CA INDEX NAME)



RN 319015-56-0 CAPLUS
CN Sulfamic acid, 4-(3-pyridinyl)phenyl ester (9CI) (CA INDEX NAME)



RN 319015-57-1 CAPLUS
CN Sulfamic acid, 4-(2-methyl-4-thiazolyl)phenyl ester (9CI) (CA INDEX NAME)



RN 319015-58-2 CAPLUS
CN Sulfamic acid, 4-[4-[(aminosulfonyl)oxy]phenyl]-2-thiazolyl ester (9CI) (CA INDEX NAME)



RN 319015-60-6 CAPLUS
CN Sulfamic acid, 4-[3-[(methylamino)carbonyl]-5-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-61-7 CAPLUS
CN Sulfamic acid, 3-chloro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-62-8 CAPLUS
CN Sulfamic acid, 3-bromo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-63-9 CAPLUS
CN Sulfamic acid, 3-iodo[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-64-0 CAPLUS
CN Sulfamic acid, 3-(acetylamino)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-66-2 CAPLUS
CN Sulfamic acid, 4'-[(methylsulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-68-4 CAPLUS
CN Sulfamic acid, 2'-[(methylsulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-70-8 CAPLUS
CN Sulfamic acid, 4'-[(methylsulfonyl)oxy][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-72-0 CAPLUS
CN Sulfamic acid, 4-[(1Z)-2-cyano-2-phenylethenyl]phenyl ester, (.alpha.Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319015-74-2 CAPLUS
CN Sulfamic acid, [(1Z)-1-cyano-1,2-ethenediyl]di-4,1-phenylene ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319015-76-4 CAPLUS
CN Sulfamic acid, 4-[(1Z)-1-cyano-2-phenylethenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319015-78-6 CAPLUS
CN Sulfamic acid, 4-[[(4-cyanophenyl)-2-pyrimidinylamino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 319015-79-7 CAPLUS
CN Sulfamic acid, dimethyl-, 2'-cyano-4'-nitro[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-80-0 CAPLUS
CN Sulfamic acid, 4'-[(aminosulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-81-1 CAPLUS
CN Sulfamic acid, 2'-[(aminosulfonyl)amino][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-83-3 CAPLUS
CN Sulfamic acid, 4-[(1Z)-2-[4-[(aminosulfonyl)amino]phenyl]-2-cyanoethenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319015-85-5 CAPLUS
CN Benzoic acid, 4-[(1Z)-2-[4-[(aminosulfonyl)oxy]phenyl]-2-cyanoethenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319015-86-6 CAPLUS
CN Sulfamic acid, 4'-amino-2'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319015-87-7 CAPLUS
CN Sulfamic acid, 2'-amino-4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

C:\STNEXP4\QUERIES\10019693 (patel).str





chain nodes :
7 8 9 10 12 13 15 16 26 27 28 37 38 39 40 41 48 55 62 123
ring nodes :
1 2 3 4 5 6 20 21 22 23 24 25 29 30 31 32 33 34 49 50 51 52 53 54
56 57 58 59 60 61 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79
80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101
102 103 104 105 106 107 108 109 110 111 112 113 114
chain bonds :
4-48 7-8 7-123 8-9 10-12 13-16 15-16 27-28 28-30 37-38 37-39 40-41 52-55 59-62
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 29-30 29-34 30-31
31-32 32-33 33-34 49-50 49-54 50-51 51-52 52-53 53-54 56-57 56-61 57-58 58-59
59-60 60-61 63-64 63-68 64-65 65-66 66-67 67-68 67-69 68-71 69-70 69-72 70-71
70-75 72-73 73-74 74-75 76-77 76-81 77-78 78-79 79-80 80-81 80-82 81-84 82-83
82-85 83-84 83-88 85-86 86-87 87-88 89-90 89-94 90-91 91-92 92-93 93-94 93-95
94-97 95-96 95-98 96-97 96-101 98-99 99-100 100-101 102-103 102-107 103-104
104-105 105-106 106-107 106-108 107-110 108-109 108-111 109-110 109-114 111-112
112-113 113-114
exact/norm bonds :
4-48 7-8 7-123 8-9 10-12 13-16 15-16 37-38 37-39 52-55 59-62 67-69 68-71 69-70
69-72 70-71 70-75 72-73 73-74 74-75 80-82 81-84 82-83 82-85 83-84 83-88 85-86
86-87 87-88 93-95 94-97 95-96 95-98 96-97 96-101 98-99 99-100 100-101 106-108
107-110 108-109 108-111 109-110 109-114 111-112 112-113 113-114
exact bonds :
27-28 28-30 40-41
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 20-21 20-25 21-22 22-23 23-24 24-25 29-30 29-34 30-31
31-32 32-33 33-34 49-50 49-54 50-51 51-52 52-53 53-54 56-57 56-61 57-58 58-59
59-60 60-61 63-64 63-68 64-65 65-66 66-67 67-68 76-77 76-81 77-78 78-79 79-80
80-81 89-90 89-94 90-91 91-92 92-93 93-94 102-103 102-107 103-104 104-105
105-106 106-107
isolated ring systems :

containing 1 : 29 : 49 : 56 :

G1:Me,CH2,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:NH2,[*1],[*2]

G3:[*3],[*4],[*5],[*6],[*7]

G4:[*8],[*9],[*10],[*11],[*12],[*13],[*14]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
12:CLASS 13:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
25:Atom 26:Atom 27:CLASS 28:CLASS 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom
37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom
52:Atom 53:Atom 54:Atom 55:CLASS 56:Atom 57:Atom 58:Atom 59:Atom 60:Atom 61:Atom
62:CLASS 63:Atom 64:Atom 65:Atom 66:Atom 67:Atom 68:Atom 69:Atom 70:Atom 71:Atom
72:Atom 73:Atom 74:Atom 75:Atom 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom
82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom 88:Atom 89:Atom 90:Atom 91:Atom
92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:Atom 98:Atom 99:Atom 100:Atom 101:Atom
102:Atom 103:Atom 104:Atom 105:Atom 106:Atom 107:Atom 108:Atom 109:Atom 110:Atom
111:Atom 112:Atom 113:Atom 114:Atom 123:CLASS
Generic attributes :
26:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 26: Limited
C,C3-5
N,N1
O,O0-1
S,S0-1

```
=>
Uploading 10019693 (patel).str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:11:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    209 TO ITERATE

100.0% PROCESSED     209 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          3313 TO     5047
PROJECTED ANSWERS:             2354 TO     3846

L2           50 SEA SSS SAM L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L3    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10019693 (patel).str

L4      STRUCTURE UPLOADED

=> que L4 NOT L3

L5   QUE L4 NOT L3

=> d l5
L5 HAS NO ANSWERS
L3              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
```

```
L4              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L5              QUE  L4 NOT L3


=> s l5 sss sam
SAMPLE SEARCH INITIATED 14:14:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    205 TO ITERATE

100.0% PROCESSED     205 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3241 TO     4959
PROJECTED ANSWERS:            1299 TO     2461

L6           50 SEA SSS SAM L4 NOT L3

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L7    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10019693 (patel).str

L8      STRUCTURE UPLOADED

=> que L8 NOT L7

L9   QUE L8 NOT L7

=> d l9
L9 HAS NO ANSWERS
L7              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.
L9              QUE  L8 NOT L7


=> s l9 sss sam
SAMPLE SEARCH INITIATED 14:25:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    212 TO ITERATE

100.0% PROCESSED     212 ITERATIONS                          10 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          3367 TO     5113
PROJECTED ANSWERS:               11 TO      389

L10          10 SEA SSS SAM L8 NOT L7

=> s l9 sss ful
FULL SEARCH INITIATED 14:26:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   4126 TO ITERATE

100.0% PROCESSED    4126 ITERATIONS                          255 ANSWERS
SEARCH TIME: 00.00.01

L11          255 SEA SSS FUL L8 NOT L7

=> s l11
L12          42 L11

=> d l12 1-42 bib,ab,hitstr
```

L12 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2003:44124 CAPLUS
DN 138:55747
TI Preparation of arylsulfamates as estrone sulfatase inhibitors
IN Ahmed, Sabbir
PA BTG International Limited, UK
SO Brit. UK Pat. Appl., 28 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2371299	A1	20020724	GB 2001-1220	20010117
PRAI GB 2001-1220		20010117		

OS MARPAT 138:55747
AB Title compds. [I; R1-R5 = H, halo, alkyl, nitro, (substituted) alkoxy, aryl, aryloxy, alkylamino, arylamino, COOR6, sulfamate group; .gtoreq.1 of R1-R5 = sulfamate group, aryl, aryloxy, or arylamino substituted with a sulfamate group; R6 = H, aryl, or alkyl], were prepd. Thus, NaH was added to a stirred soln. of Me 4-hydroxybenzoate (prepn. given) in DMF at 0.degree.; after 30 min. aminosulfonyl chloride in PhMe was added and the reaction allowed to stir for 10 h to give 31.6% Me 4-[(aminosulfonyl)oxy]benzoate. The latter inhibited estrone sulfatase by 74.7% at 50 .mu.M.
IT **319014-71-6P**, Methyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-63-3P**, Ethyl 4'-[(aminosulfonyl)oxy]-1,1'-biphenyl-4-carboxylate **471269-64-4P**, Propyl 4'-[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate **471269-65-5P**, Butyl 4'-[(aminosulfonyl)oxy]-1'-biphenyl-4-carboxylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylsulfamates as estrone sulfatase inhibitors)
RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2002:845557 CAPLUS
DN 137:353213
TI Preparation of sulfamates with a steroid nucleus as steroid sulfatase inhibitors for treating breast cancer
IN Reed, Michael John; Potter, Barry Victor Lloyd
PA Sterix Ltd., USA
SO U.S., 55 pp., Cont. of U.S. Ser. No. 125,255.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6476011	B1	20021105	US 1998-193970	19981118
	WO 9305064	A1	19930318	WO 1992-GB1587	19920828
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	EP 921130	A2	19990609	EP 1998-204340	19920828
	EP 921130	A3	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	EP 928609	A2	19990714	EP 1998-204337	19920828
	EP 928609	A3	20011107		
	EP 928609	B1	20030416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000038341	A2	20000208	JP 1999-211413	19920828
	EP 982032	A2	20000301	EP 1999-203449	19920828
	EP 982032	A3	20020320		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000355542	A2	20001226	JP 2000-163410	19920828
	JP 2000355598	A2	20001226	JP 2000-163411	19920828
	EP 1099706	A2	20010516	EP 2000-204525	19920828
	EP 1099706	A3	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2002255993	A2	20020911	JP 2002-17765	19920828
	US 5616574	A	19970401	US 1994-196192	19941227
	US 5830886	A	19981103	US 1995-458352	19950602
	WO 9730041	A1	19970821	WO 1997-GB444	19970217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 9732872	A1	19970912	WO 1997-GB600	19970304
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 9824802	A2	19980611	WO 1997-GB3352	19971204

	WO 9824802	A3	19980827			
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	US 6011024	A	20000104	US 1998-111927	19980708	
	US 6239169	B1	20010529	US 1998-125255	19980814	
	US 6083978	A	20000704	US 1998-142194	19980902	
	AU 9910077	A1	19990304	AU 1999-10077	19990111	
	AU 717116	B2	20000316			
	AU 726811	B2	20001123	AU 2000-10130	20000106	
	US 2002177619	A1	20021128	US 2002-82007	20020221	
PRAI	GB 1991-18478	A	19910829			
	WO 1992-GB1587	A3	19920828			
	US 1994-196192	A3	19941227			
	US 1995-458352	A2	19950602			
	WO 1997-GB444	A2	19970217			
	WO 1997-GB600	A2	19970304			
	WO 1997-GB3352	A2	19971204			
	US 1998-111927	A2	19980708			
	US 1998-125255	A2	19980814			
	US 1998-142194	A2	19980902			
	EP 1992-918285	A3	19920828			
	EP 1998-204340	A3	19920828			
	JP 1993-505032	A3	19920828			
	JP 2000-163410	A3	19920828			
	GB 1996-3325	A	19960216			
	GB 1996-4709	A	19960305			
	GB 1996-5725	A	19960319			
	GB 1996-25334	A	19961205			
	AU 1998-71952	A3	19980618			
	US 1998-193970	A3	19981118			
	AU 1999-10077	A	19990111			

OS MARPAT 137:353213

AB The invention pertains to methods for introducing an estrogenic compd. into a subject in need thereof involving administering an effective amt. of a ring system compd. having the formula (I) wherein each of R1 and R2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl, and at least one of R1 and R2 is H, or together represent alkylene optionally contg. one or more hetero atoms or groups in the alkylene chain; and the ring system ABCD represents a substituted or unsubstituted, satd. or unsatd. steroid nucleus selected from the group consisting of estrones, dehydroepiandrosterones, substituted estrones, estradiols, substituted estradiols, estriols, substituted dehydroepiandrosterones, or substituted estriols; wherein the compd. is an inhibitor of an enzyme having steroid sulfatase activity (EC 3.1.6.2), or a pharmaceutically acceptable salt thereof. The compds. have application for treating breast cancer.

IT **243129-61-5P**, Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfamates with a steroid nucleus as steroid sulfatase inhibitors for treating breast cancer)

RN 243129-61-5 CAPLUS
CN Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2002:482277 CAPLUS
DN 138:66153
TI The design, synthesis, and biochemical evaluation of derivatives of biphenyl sulfamate-based compounds as novel inhibitors of estrone sulfatase
AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.
CS School of Chemical and Pharmaceutical Sciences, Kingston University, Surrey, Kingston upon Thames, KT1 2EE, UK
SO Biochemical and Biophysical Research Communications (2002), 294(1), 180-183
CODEN: BBRCA9; ISSN: 0006-291X
PB Elsevier Science
DT Journal
LA English
OS CASREACT 138:66153
AB We report the initial results of our study into the use of a potential transition state (TS) of the reaction catalyzed by the enzyme estrone sulfatase (ES) in the design of a series of simple 4'-O-sulfamoyl-4-biphenyl-based compds. as novel inhibitors of ES. The results of the study show that these compds. are: potent inhibitors, possessing greater inhibitory activity than 4-methylcoumarin-7-O-sulfamate (COUMATE); weaker inhibitors than the tricyclic deriv. of COUMATE, namely 667-COUMATE and the steroidal inhibitor estrone-3-O-sulfamate (EMATE), and irreversible inhibitors of ES.
IT **25999-01-3P**
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT **319014-71-6P 319014-72-7P 471269-63-3P**
471269-64-4P 471269-65-5P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design, synthesis, and biochem. evaluation of derivs. of biphenyl sulfamate-based compds. as novel inhibitors of estrone sulfatase)
RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 319014-72-7 CAPLUS
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2002:324919 CAPLUS
DN 137:310661
TI Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES)
AU Ahmed, Sabbir; James, Karen; Owen, Caroline P.; Patel, Chirag K.
CS School of Chemical and Pharmaceutical Sciences, Kingston University, Kingston upon Thames, Surrey, KT1 2EE, UK
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(10), 1343-1346
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB 4-(4-RC6H4)C6H4O3SNH2 [= H, CN, CO2Me, CO2Et, CO2Pr, CO2Bu] were prepd.as novel inhibitors of the enzyme estrone sulfatase (ES). The results of the study show that these compds. are potent inhibitors, possessing greater inhibitory activity than coumate, but weaker inhibitory activity than emate or the tricyclic deriv. of coumate, namely 667-coumate. Furthermore, the compds. are obsd. to be irreversible inhibitors.
IT **25999-01-3P 319014-71-6P 319014-72-7P 471269-63-3P 471269-64-4P 471269-65-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and estrone sulfatase inhibiting activity of sulfamoyloxybiphenyls as steroid AC ring mimics)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 319014-71-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 319014-72-7 CAPLUS
CN Sulfamic acid, 4'-cyano[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 471269-63-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 471269-64-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, propyl ester (9CI) (CA INDEX NAME)



RN 471269-65-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]-, butyl ester (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2002:240724 CAPLUS
DN 136:263092
TI Preparation of 3,4-dihydropyrroles as pesticides
IN Plant, Andrew; Marhold, Albrecht; Grosser, Rolf; Erdelen, Christoph; Turberg, Andreas; Hansen, Olaf
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002024644	A1	20020328	WO 2001-EP10430	20010910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10051395	A1	20020411	DE 2000-10051395	20001017
AU 2001087722	A5	20020402	AU 2001-87722	20010910
PRAI DE 2000-10047119	A	20000922		
DE 2000-10051395	A	20001017		
WO 2001-EP10430	W	20010910		

OS MARPAT 136:263092
AB Title compds. [I; n = 0, 1; r, s = 0-2; R1 = halo, Me; R2 = H, halo; R3, R4 = halo, (halo)alkyl, (halo)alkoxy; R5 = (halo)alkyl, (substituted) Ph, NR6R7; R6 = (halo)alkyl; R7 = H, (halo)alkyl, R6R7 = (alkoxy)alkylene] were prepd. Thus, 4-[5-(2,6-difluorophenyl)-3,4-dihydro-2H-pyrrol-2-yl]phenol in PhMe was treated with 45% NaOH and 4-(trifluoromethoxy)benzenesulfonyl chloride, followed by stirring for 12 h at 45.degree., to give 70% 5-(2,6-difluorophenyl)-2-(4-[4-(trifluoromethoxy)phenyl]sulfonyloxyphenyl)-3,4-dihydro-2H-pyrrole. Several I at 100-200 ppm gave 90-95% kill of Aphis gossypii on Gossypium hirsutum after 6 days.
IT **405201-75-4P**
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dihydropyrroles as pesticides)
RN 405201-75-4 CAPLUS
CN Sulfamic acid, dimethyl-, 4'-[5-(2,6-difluorophenyl)-3,4-dihydro-2H-pyrrol-2-yl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT **405201-79-8P 405201-83-4P 405201-84-5P 405201-85-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of dihydropyrroles as pesticides)

RN 405201-79-8 CAPLUS
CN Carbamic acid, [4-(2,6-difluorophenyl)-1-[4'-[[(dimethylamino)sulfonyl]oxy][1,1'-biphenyl]-4-yl]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 405201-83-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[4'-[[(dimethylamino)sulfonyl]oxy][1,1'-biphenyl]-4-yl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 405201-84-5 CAPLUS
CN Sulfamic acid, dimethyl-, 4'-(5-oxo-2-pyrrolidinyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 405201-85-6 CAPLUS
CN Sulfamic acid, dimethyl-, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2002:63493 CAPLUS
DN 136:112635
TI Biphenylyl sulfamates as steroid sulfatase inhibitors for estrogen-dependent diseases
IN Jinbo, Yoshikazu; Miyasaka, Tomohiro; Inoue, Yoshimasa
PA Japan Organo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002020362	A2	20020123	JP 2000-245314	20000706
PRAI JP 2000-245314		20000706		

OS MARPAT 136:112635
AB 4-RC6H4C6H4OSO2NH2-4 [I; R = CO2H, CONR1R2, CONR1OCH2Ph, COR2, C(OH)R1R2; R1 = H, (un)substituted alkyl; 2 = (un)substituted alkyl] are prepd. I are useful for treatment of mammary cancer, endometrial cancer, endometriosis, uterine myoma, etc. I (R = COCH2C6H4CMe3-4) (prepn. given) inhibited human placenta-derived steroid sulfatase at IC50 3.6 .mu.M.
IT **390358-08-4P 390358-09-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of biphenylyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)
RN 390358-08-4 CAPLUS
CN Sulfamic acid, 4'-acetyl[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-09-5 CAPLUS
CN Sulfamic acid, 4'-[[4-(1,1-dimethylethyl)phenyl]acetyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



IT **390358-11-9P 390358-12-0P 390358-14-2P**
390358-16-4P 390358-17-5P 390358-19-7P
390358-21-1P 390358-23-3P 390358-25-5P
390358-27-7P 390358-29-9P 390358-31-3P
390358-33-5P 390358-34-6P 390358-35-7P

390358-36-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biphenylyl sulfamates as steroid sulfatase inhibitors for treatment of estrogen-dependent diseases)

RN 390358-11-9 CAPLUS
CN Sulfamic acid, 4'-(1-oxopentyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-12-0 CAPLUS
CN Sulfamic acid, 4'-(1-oxoheptyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-14-2 CAPLUS
CN Sulfamic acid, 4'-[(ethylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-16-4 CAPLUS
CN Sulfamic acid, 4'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-17-5 CAPLUS
CN Sulfamic acid, 4'-[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-19-7 CAPLUS
CN Sulfamic acid, 4'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-21-1 CAPLUS
CN Sulfamic acid, 4'-[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-23-3 CAPLUS
CN Sulfamic acid, 4'-[[(phenylmethoxy)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-25-5 CAPLUS
CN Sulfamic acid, 4'-[[methyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-27-7 CAPLUS
CN Sulfamic acid, 4'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]methylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-29-9 CAPLUS
CN Sulfamic acid, 4'-[[butyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-31-3 CAPLUS
CN Sulfamic acid, 4'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]octylamino]carbonyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-33-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[(aminosulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 390358-34-6 CAPLUS
CN Sulfamic acid, 4'-(1-hydroxyethyl)[1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-35-7 CAPLUS
CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxyethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 390358-36-8 CAPLUS
CN Sulfamic acid, 4'-[2-[4-(1,1-dimethylethyl)phenyl]-1-hydroxy-1-methylethyl][1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2001:668347 CAPLUS
DN 135:226790
TI Preparation of aryl sulfamates for the treatment of estrogen-dependent illnesses
IN Li, Pui-kai; Selcer, Kyle W.
PA Duquesne University of the Holy Ghost, USA
SO U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 164,889.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6288107	B1	20010911	US 2000-536331	20000324
	US 6248780	B1	20010619	US 1998-164889	19981001
	US 6433000	B1	20020813	US 2001-845850	20010430
	US 2003008862	A1	20030109	US 2002-174092	20020618
PRAI	US 1998-164889	A2	19981001		
	US 2000-536331	A3	20000324		
	US 2001-845850	A3	20010430		

OS MARPAT 135:226790
AB Sulfatase inhibitor/estrogen receptor blocker compds. (I) [wherein R = estrogen receptor blocker; R1 and R2 = independently H or alkyl] useful in the treatment of estrogen-dependent illnesses, such as breast cancer, vaginal cancer, endometrial cancer, ovarian cancer, and endometriosis, are disclosed. Prepn. and testing of 7,8-dihydro-5,6-diphenylnaphthalen-2-yl sulfamates and (Z)-4-hydroxytamoxifen sulfamate are described, and 3-benzoyl-2-phenylbenzothiophen-6-yl sulfamates (no prepn.) are claimed. Thus, 1-bromo-4-[2-(tributylsiloxy)ethoxy]benzene was treated with BuLi and then coupled with 6-(tetrahydropyranyloxy)tetralone (prepn. of reactants given) to afford the protected dihydronaphthalene (65.7%). Deprotection and bromination using pyridinium tribromide (90.3%), followed by arylation with PhLi (94%), iodination (95%), amination with NHMe2 (88.3%), and reaction with sulfamoyl chloride (91.6%), gave II. In a sulfatase activity assay, II inhibited estrone sulfatase in rat liver microsomes at 20 .mu.M substrate estrone sulfate by over 60% compared to the control.
IT **221214-41-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl sulfamates for treatment of estrogen-dependent illnesses)
RN 221214-41-1 CAPLUS
CN Sulfamic acid, 4-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2001:338504 CAPLUS
DN 134:340518
TI Substituted 5-benzyl-2,4-diaminopyrimidines
IN Guerry, Philippe; Mohr, Peter; Muller, Marc; Mueller, Werner; Pflieger, Philippe
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 177 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001032633	A1	20010510	WO 2000-CH575	20001027
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1230224	A1	20020814	EP 2000-969149	20001027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI CH 1999-2021	A	19991104		
WO 2000-CH575	W	20001027		

OS MARPAT 134:340518
AB Substituted 5-benzyl-2,4-diaminopyrimidines I [R1 = C2-C3 alkyl; R2 = (un)substituted heterocyclyl, Ph, naphthyl; R3 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclylsulfonyl, heterocyclyalkylsulfonyl, dialkylsulfamoyl] were prepd. for use as antibacterial agents. Thus, I [R1 = R3 = Et, R2 = I] was prepd. from 3,5-(HO)2C6H3CO2H by iodination, esterification, etherification, redn. to 4,3,5-I(EtO)2C6H2CHO via 4,3,5-I(EtO)2C6H2CH2OH, reaction with PhNHCH2CH2CN, and cyclization with guanidine-HCl. I [R1 = R3 = Et, R2 = I] was coupled with 3-H2NC6H4B(OH)2 to give I [R1 = R3 = Et, R2 = 3-H2NC6H4] which had an IC50 against dihydrofolate reductase from Streptococcus pneumoniae 1/1 of 0.19 .mu.M.
IT **338456-51-2P 338457-64-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of substituted 5-benzyl-2,4-diaminopyrimidines as bacterial dihydrofolate reductase inhibitors)
RN 338456-51-2 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338457-64-0 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylthio)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



IT **338456-43-2P 338456-46-5P 338456-48-7P**
338456-50-1P 338456-55-6P 338456-57-8P
338456-58-9P 338456-59-0P 338456-60-3P
338456-61-4P 338456-65-8P 338456-71-6P
338456-72-7P 338456-76-1P 338456-79-4P
338456-80-7P 338456-82-9P 338456-83-0P
338456-87-4P 338456-88-5P 338456-90-9P
338456-92-1P 338456-94-3P 338456-95-4P
338457-65-1P 338457-66-2P 338457-67-3P
338457-92-4P 338457-95-7P 338457-98-0P
338458-02-9P 338458-06-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted 5-benzyl-2,4-diaminopyrimidines as bacterial dihydrofolate reductase inhibitors)
RN 338456-43-2 CAPLUS
CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-46-5 CAPLUS
CN Sulfamic acid, methyl(1-methylethyl)-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-48-7 CAPLUS
CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-50-1 CAPLUS
CN Sulfamic acid, diethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-55-6 CAPLUS
CN Sulfamic acid, methyl(1-methylethyl)-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-57-8 CAPLUS
CN Sulfamic acid, ethylmethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-58-9 CAPLUS
CN Sulfamic acid, diethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-hydroxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-59-0 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-methoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-60-3 CAPLUS
CN Sulfamic acid, dimethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-61-4 CAPLUS
CN Sulfamic acid, ethylmethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-65-8 CAPLUS
CN Sulfamic acid, diethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-71-6 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylamino)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-72-7 CAPLUS
CN Sulfamic acid, ethylmethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylamino)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-76-1 CAPLUS
CN Sulfamic acid, diethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylamino)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-79-4 CAPLUS
CN Sulfamic acid, dimethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-methyl[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-80-7 CAPLUS
CN Sulfamic acid, ethylmethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-methyl[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-82-9 CAPLUS
CN Sulfamic acid, dimethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-fluoro[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-83-0 CAPLUS
CN Sulfamic acid, ethylmethyl-, 4'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-fluoro[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-87-4 CAPLUS
CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-5'-fluoro[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-88-5 CAPLUS
CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-5'-fluoro[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-90-9 CAPLUS
CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-92-1 CAPLUS
CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-94-3 CAPLUS
CN Sulfamic acid, dimethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-methyl[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338456-95-4 CAPLUS
CN Sulfamic acid, ethylmethyl-, 3'-amino-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-methyl[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338457-65-1 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338457-66-2 CAPLUS
CN Sulfamic acid, dimethyl-, 4'-amino-3'-cyano-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338457-67-3 CAPLUS
CN Sulfamic acid, dimethyl-, 5-[(2,4-diamino-5-pyrimidinyl)methyl]-3-ethoxy-2-(1H-indol-5-yl)phenyl ester (9CI) (CA INDEX NAME)



RN 338457-92-4 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(methylsulfonyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338457-95-7 CAPLUS
CN Sulfamic acid, dimethyl-, 4'-(acetyloxy)-4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338457-98-0 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-3'-fluoro-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338458-02-9 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-(4-morpholinylmethyl)[1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RN 338458-06-3 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[(2,4-diamino-5-pyrimidinyl)methyl]-6-ethoxy-4'-[[(2-fluoroethyl)methylamino]methyl][1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2000:875743 CAPLUS
DN 134:29611
TI Preparation of O-sulfamoylphenols for pharmaceutical use as steroid sulfatase inhibitors
IN Reed, Michael John; Potter, Barry Victor Lloyd
PA Sterix Limited, UK
SO U.S., 56 pp., Cont.-in-part of U.S. 6,011,024.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6159960	A	20001212	US 1998-193969	19981118
	EP 921130	A2	19990609	EP 1998-204340	19920828
	EP 921130	A3	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	EP 928609	A2	19990714	EP 1998-204337	19920828
	EP 928609	A3	20011107		
	EP 928609	B1	20030416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000038341	A2	20000208	JP 1999-211413	19920828
	EP 982032	A2	20000301	EP 1999-203449	19920828
	EP 982032	A3	20020320		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2000355542	A2	20001226	JP 2000-163410	19920828
	JP 2000355598	A2	20001226	JP 2000-163411	19920828
	EP 1099706	A2	20010516	EP 2000-204525	19920828
	EP 1099706	A3	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
	JP 2002255993	A2	20020911	JP 2002-17765	19920828
	US 5830886	A	19981103	US 1995-458352	19950602
	US 6011024	A	20000104	US 1998-111927	19980708
	AU 9910077	A1	19990304	AU 1999-10077	19990111
	AU 717116	B2	20000316		
	AU 726811	B2	20001123	AU 2000-10130	20000106
PRAI	GB 1991-18478	A	19910829		
	US 1995-458352	A2	19950602		
	US 1998-111927	A2	19980708		
	EP 1992-918285	A3	19920828		
	EP 1998-204340	A3	19920828		
	JP 1993-505032	A3	19920828		
	JP 2000-163410	A3	19920828		
	US 1994-196192	A3	19941227		
	WO 1997-GB444	A2	19970217		
	WO 1997-GB600	A2	19970304		
	WO 1997-GB3352	A2	19971204		
	AU 1998-71952	A3	19980618		
	AU 1999-10077	A	19990111		

OS MARPAT 134:29611
AB O-sulfamoylphenols, R1R2N-SO2-OR [R = aryl bonded through a benzene subunit, such as Ph, estra-1,3,5(10)-trien-3-yl, coumarinyl, flavonyl, flavanyl, isoflavonyl; R1, R2 = H, alkyl, alkenyl, cycloalkyl, aryl], were prepd. for use as steroid sulfatase inhibitors for the treatment of diseases, such as breast cancer. Thus, osterone was reacted with sulfamoyl chloride using NaH in DMF to give sulfamate I. The prepd. sulfamates were tested for inhibiting activity against steroid sulfatase

enzyme (E.C.3.1.6.2).

IT **243129-61-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of O-sulfamoylphenols for pharmaceutical use as steroid sulfatase inhibitors)

RN 243129-61-5 CAPLUS

CN Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2000:227501 CAPLUS
DN 132:260691
TI Aromatic sulfamate derivative sulfatase inhibitor/estrogen receptor blocker compounds for the treatment of estrogen-dependent illnesses, and methods for preparation and use
IN Li, Pui-Kai; Selcer, Kyle W.
PA Duquesne University of the Holy Ghost, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018397	A1	20000406	WO 1999-US22823	19990930
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6248780	B1	20010619	US 1998-164889	19981001
	CA 2345988	AA	20000406	CA 1999-2345988	19990930
	AU 9964081	A1	20000417	AU 1999-64081	19990930
	AU 748958	B2	20020613		
	EP 1117395	A1	20010725	EP 1999-951694	19990930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002525322	T2	20020813	JP 2000-571915	19990930
PRAI	US 1998-164889	A	19981001		
	WO 1999-US22823	W	19990930		

OS MARPAT 132:260691
AB Sulfatase inhibitor/estrogen receptor blocker compds. useful in the treatment of estrogen dependent illnesses are disclosed. The compds. generally comprise a sulfamate moiety and an arom., estrogen receptor blocker moiety. Methods for synthesizing these compds. and using them in the therapeutic and/or prophylactic treatment of an estrogen-dependent disease are also disclosed. Prepn. and testing of (Z)-4-hydroxytamoxifen sulfamate is described.
IT **221214-42-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(arom. sulfamate deriv. sulfatase inhibitor/estrogen receptor blocker compds. for the treatment of estrogen-dependent illnesses, and methods for prepn. and use)
RN 221214-42-2 CAPLUS
CN Sulfamic acid, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2000:190770 CAPLUS
DN 132:222555
TI Preparation of interleukin-5 inhibiting 6-azauracil derivatives
IN Freyne, Eddy Jean Edgard; Lacrampe, Jean Fernand Armand; Deroose, Frederik Dirk; Venet, Marc Gaston
PA Janssen Pharmaceutica N.V., Belg.
SO Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 987265	A1	20000322	EP 1998-203148	19980918
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2344390	AA	20000330	CA 1999-2344390	19990914
	WO 2000017195	A1	20000330	WO 1999-EP6776	19990914
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9960825	A1	20000410	AU 1999-60825	19990914
	EP 1114046	A1	20010711	EP 1999-947336	19990914
	EP 1114046	B1	20030423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002526495	T2	20020820	JP 2000-574104	19990914
	US 2002010177	A1	20020124	US 2001-812731	20010319
PRAI	EP 1998-203148	A	19980918		
	WO 1999-EP6776	W	19990914		

OS MARPAT 132:222555
AB The title compds. [I; p = 0-4; X = O, S, NR5, a direct bond; Y = O, S, NR5, SO2; R1 = alkyl, halo, polyhaloalkyl, etc.; R2 = Het1, cycloalkyl, alkyl, and if X = O, S, NR5, then R2 may also represent aminocarbonyl, aminothiocarbonyl, alkylcarbonyl, etc.; R3, R4 = H, alkyl, cycloalkyl; R3R4 = alkanediyl; R5 = H, alkyl; Het1 = (un)substituted heterocycle], useful for treating eosinophil-dependent inflammatory diseases, and marking a receptor, were prepd. and formulated. E.g., a multi-step synthesis of 1,2,4-triazine-3,5(2H,4H)-dione II which showed 90.5% inhibition of IL-5 prodn., was given.
IT **261512-01-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of interleukin-5 inhibiting 6-azauracil derivs.)
RN 261512-01-0 CAPLUS
CN Sulfamic acid, 3-[2-[1-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)phenyl]-1-methylethyl]-4-phenyl-5-thiazolyl]phenyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2000:84826 CAPLUS
DN 132:137416
TI Preparation of 6-[[[[phosphono(oxy)]aryl]alkanoyl]amino]-1,4-thiazepin-5-ones and analogs as protein tyrosine kinase c-Src inhibitors
IN Benard, Didier; Deprez, Pierre; Lesuisse, Dominique; Mandine, Eliane; Ugolini, Antonio
PA Hoechst Marion Roussel, Fr.
SO PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005246	A1	20000203	WO 1999-FR1770	19990720
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2781483	A1	20000128	FR 1998-9258	19980721
	AU 9949133	A1	20000214	AU 1999-49133	19990720
PRAI	FR 1998-9258	A	19980721		
	WO 1999-FR1770	W	19990720		

OS MARPAT 132:137416
AB Title compds. [I; R = NHZZ1Z2R7; R1,R2 = H, OH, alkyl, alkoxy, etc.; R1R2 = atoms to complete a (hetero)arom. ring; R3,R4 = H, alkyl, aryl(alkyl), etc.; R5 = H, alk(en)yl, aryl(alkyl), etc.; R7 = P(O)(OH)2, OP(O)(OH)2, bis(alkoxy)phosphoryl(oxy), CH2CO2H, SO2NH2, etc.; Z = CO, SO2, alk(en)ylene, etc.; Z1 = CHR6(CH2)1-4, CR6:CHCH2, CHR6, etc.; R6 = H, (acyl)amino, tetrazolyl, etc.; Z2 = arylene; dashed line = optional addnl. bond] were prepd. Thus, (S)-HSCH2CH(NH2)CO2Me was cyclocondensed with CLCH2CH2NH2 and the product amidated by (S)-HO2CCH(NHBoc)CH2C6H4[OP(O)(OCH2Ph)2]-4 to give, in 2 addnl. steps, [S-[R*(6S*)]]-I [R = NHCOCH(NHBoc)CH2C6H4[OP(O)(OCH2Ph)2]-4, R1-R4 = H, R5 = 3-cyclohexylpropyl, dashed line = null]. Data for biol. activity of I were given.
IT **256655-91-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 6-[[[[phosphono(oxy)]aryl]alkanoyl]amino]-1,4-thiazepin-5-ones and analogs as protein tyrosine kinase c-Src inhibitors)
RN 256655-91-1 CAPLUS
CN Sulfamic acid, 4-[[[(6R)-hexahydro-5-oxo-4-(3-phenyl-2-propenyl)-1,4-thiazepin-6-yl]amino]carbonyl]phenyl ester- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 2000:10623 CAPLUS
DN 132:78747
TI Preparation and formulation of steroid sulphatase inhibitors for use in cancer treatment
IN Reed, Michael John; Potter, Barry Victor Lloyd
PA Imperial College of Science Technology and Medicine, UK
SO U.S., 56 pp., Cont.-in-part of U.S. 5,830,886.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6011024	A	20000104	US 1998-111927	19980708
EP 921130	A2	19990609	EP 1998-204340	19920828
EP 921130	A3	20010905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
EP 928609	A2	19990714	EP 1998-204337	19920828
EP 928609	A3	20011107		
EP 928609	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
JP 2000038341	A2	20000208	JP 1999-211413	19920828
EP 982032	A2	20000301	EP 1999-203449	19920828
EP 982032	A3	20020320		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
JP 2000355542	A2	20001226	JP 2000-163410	19920828
JP 2000355598	A2	20001226	JP 2000-163411	19920828
EP 1099706	A2	20010516	EP 2000-204525	19920828
EP 1099706	A3	20020904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
JP 2002255993	A2	20020911	JP 2002-17765	19920828
US 5616574	A	19970401	US 1994-196192	19941227
US 5830886	A	19981103	US 1995-458352	19950602
WO 9730041	A1	19970821	WO 1997-GB444	19970217
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9732872	A1	19970912	WO 1997-GB600	19970304
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9824802	A2	19980611	WO 1997-GB3352	19971204
WO 9824802	A3	19980827		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,				

US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	US 6159960	A	20001212	US 1998-193969	19981118
	US 6476011	B1	20021105	US 1998-193970	19981118
	AU 9910077	A1	19990304	AU 1999-10077	19990111
	AU 717116	B2	20000316		
	US 6187766	B1	20010213	US 1999-238345	19990127
	AU 726811	B2	20001123	AU 2000-10130	20000106
	US 6506792	B1	20030114	US 2000-638315	20000814
	US 2001018435	A1	20010830	US 2001-794853	20010227
	US 2002177619	A1	20021128	US 2002-82007	20020221
	US 2002128243	A1	20020912	US 2002-84235	20020225
PRAI	GB 1991-18478	A	19910829		
	US 1994-196192	A3	19941227		
	US 1995-458352	A2	19950602		
	WO 1997-GB444	A2	19970217		
	WO 1997-GB600	A2	19970304		
	WO 1997-GB3352	A2	19971204		
	EP 1992-918285	A3	19920828		
	EP 1998-204340	A3	19920828		
	JP 1993-505032	A3	19920828		
	JP 2000-163410	A3	19920828		
	WO 1992-GB1587	W	19920828		
	GB 1996-3325	A	19960216		
	GB 1996-4709	A	19960305		
	GB 1996-5725	A	19960319		
	GB 1996-25334	A	19961205		
	AU 1998-71952	A3	19980618		
	US 1998-111927	A2	19980708		
	US 1998-125255	A2	19980814		
	US 1998-142194	A2	19980902		
	US 1998-193970	A3	19981118		
	AU 1999-10077	A	19990111		
	US 1999-238345	A2	19990127		
	US 2000-579163	A3	20000525		

OS MARPAT 132:78747

AB Steroid sulfatase inhibitors, R1R2NSO2OR [R = arom. ring, such as Ph, estra-1,3,5(10)-trien-3-yl, coumarinyl, flavonoid; R1, R2 = H, alkyl, alkenyl, cycloalkyl, aryl; R1R2 = alkylene], were prepd. for use in the treatment of estrogen dependent tumors. Thus, sulfamate I was prepd. by sulfamoylation of oestrone with sulfamoyl chloride. The prepd. compds. were tested for steroid sulfatase enzyme, E.C. 3.1.6.2, and aromatase inhibiting activity.

IT **243129-61-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and formulation of steroid sulfatase inhibitors for use in treatment of cancer)

RN 243129-61-5 CAPLUS

CN Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1999:437570 CAPLUS
DN 131:208593
TI Recent advances in the development of steroid sulfatase inhibitors
AU Purohit, A.; Hejaz, H. A. M.; Woo, L. W. L.; Van Strien, A. E.; Potter, B. V. L.; Reed, M. J.
CS Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary's Hospital, London, W2 1NY, UK
SO Journal of Steroid Biochemistry and Molecular Biology (1999), 69(1-6), 227-238
CODEN: JSBBEZ; ISSN: 0960-0760
PB Elsevier Science Ltd.
DT Journal
LA English
AB Inhibition of steroid sulfatase is now an important target for the development of new drugs for the treatment of women with endocrine-dependent breast tumors. The first potent sulfatase inhibitor identified, estrone-3-O-sulfamate (EMATE) proved, unexpectedly, to be estrogenic. A no. of strategies have therefore been adopted to design and synthesize a nonoestrogenic inhibitor. For this, a no. of modifications have been made to the A and D rings of the estrone nucleus. Methoxyestrone-3-O-sulfamate, while having similar in vitro and in vivo sulfatase inhibitory potency to that of EMATE, was devoid of estrogenic activity when tested at 2 mg/kg in an ovariectomized rat uterine wt. gain assay. 17-Deoxyestrone-3-O-sulfamate was also a potent steroid sulfatase inhibitor and while it was devoid of estrogenic activity when tested at 0.1 mg/kg, did stimulate uterine growth at 1.0 mg/kg. As an alternative approach to the use of steroid-based inhibitors a no. of single ring, bicyclic non-fused ring, and two fused ring sulfamate analogs were designed, synthesized and tested for their ability to inhibit steroid sulfatase activity. In general, although the single ring and bicyclic non-fused ring sulfamate analogs could inhibit sulfatase activity, they were considerably less potent than EMATE. The mono- and bis-sulfamate derivs. of 5,7-dihydroxyisoflavone were relatively potent, inhibiting in vivo steroid sulfatase activity by 62 and 81%, resp., at a single oral dose of 10 mg/kg. A study of the structure-activity relationship of a series of coumarin-based sulfamates has led to the development of a no. of potent non-steroidal inhibitors, one of which has a similar potency to that of EMATE. The identification of potent steroid- and non-steroid-based sulfatase inhibitors will enable the therapeutic value of this therapy to be examd. in the near future.
IT **243129-61-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure-activity relationship of steroid sulfatase inhibitors)
RN 243129-61-5 CAPLUS
CN Sulfamic acid, 2-methoxy-4-[[[(6E)-8-methyl-1-oxo-6-nonenyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1999:204107 CAPLUS
DN 131:27557
TI Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors
AU Kolli, Aparna; Chu, Guo-Hua; Rhodes, Michael E.; Inoue, Kengo; Selcer, Kyle W.; Li, Pui-Kai
CS Department of Biology, Bayer School of Natural and Environmental Sciences, Duquesne University, Pittsburgh, PA, 15282, USA
SO Journal of Steroid Biochemistry and Molecular Biology (1999), 68(1-2), 31-40
CODEN: JSBBEZ; ISSN: 0960-0760
PB Elsevier Science Ltd.
DT Journal
LA English
AB Estrogen levels in breast tumors of postmenopausal women are as much as 10 times higher than estrogen levels in plasma, presumably due to in situ formation of estrogen. The major source of estrogen in breast cancer cells may be conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. Thus, inhibitors of estrone sulfatase are potential agents for treatment of estrogen-dependent breast cancer. Several steroidal compds. have been developed that are potent estrone sulfatase inhibitors, most notably estrone-3-O-sulfamate. However, these compds. and their metabolites may have undesired effects, including estrogenicity. To avoid the problems assocd. with a potentially active steroid nucleus, we designed and synthesized a series of nonsteroidal estrone sulfatase inhibitors, the (p-O-sulfamoyl)-N-alkanoyl phenylalkyl amines. The compds. synthesized vary in the length of their alkanoyl chain and in the no. of carbons sepg. the Ph ring and the carbonyl carbon. The ability of these compds. to inhibit estrone sulfatase activity was tested using human placental microsomes and intact cultured human breast cancer cells. Estrogenicity was also evaluated, using growth of estrogen-dependent human breast cancer cells. All of the test compds. inhibited estrone sulfatase activity of human placental microsomes to some extent, with the most effective compd. having an IC50 value of 72 nM. In general, compds. with longer alkanoyl chains (12-14 carbons) were more effective than those with shorter chains. The test compds. also inhibited estrone sulfatase activity in intact cultures of MDA-MB-231 human breast cancer cells. Again, the longer chain compds. were more effective. In both the placental and breast cancer cell sulfatase assays, the optimal distance between the Ph ring and the carbonyl carbon was 1-2 carbons. The MCF-7 cell proliferation assay revealed that estrone and estrone-3-O-sulfamate were both estrogenic, but the (p-O-sulfamoyl)-N-alkanoyl phenylalkyl amines were not. Our data indicate the utility of (p-O-sulfamoyl)-N-alkanoyl Ph alkylamines for inhibition of estrone sulfatase activity. Furthermore, our data support the concept that nonsteroidal estrone sulfatase inhibitors may be useful as therapeutic agents for estrogen-dependent breast cancers.
IT **226950-54-5P 226950-55-6P 226950-56-7P 226950-57-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors)
RN 226950-54-5 CAPLUS
CN Sulfamic acid, 4-[[(1-oxooctyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)

C:\STNEXP4\QUERIES\10019693 (patel - amended).str





chain nodes :
7 8 9
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15
chain bonds :
2-7 7-8 8-9
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
2-7 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS



RN 226950-55-6 CAPLUS
CN Sulfamic acid, 4-[[(1-oxodecyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 226950-56-7 CAPLUS
CN Sulfamic acid, 4-[[(1-oxododecyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RN 226950-57-8 CAPLUS
CN Sulfamic acid, 4-[[(1-oxotetradecyl)amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1999:118506 CAPLUS
DN 130:237337
TI Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates
AU Chu, Guo-Hua; Peters, Amy; Selcer, Kyle W.; Li, Pui-Kai
CS Department of Medicinal Chemistry and Pharmaceutics, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, 15282, USA
SO Bioorganic & Medicinal Chemistry Letters (1999), 9(2), 141-144
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB We report the development of (E)- (I) and (Z)-4-hydroxytamoxifen sulfamates as estrone sulfatase inhibitors, potential therapeutic agents for the treatment of breast cancer. Both compds. competitively inhibit estrone sulfatase isolated from rat liver with an apparent Ki of 35.9 .mu.M for I and an apparent Ki of >500 .mu.M for the Z isomer.
IT **221214-41-1P 221214-42-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and sulfatase inhibitory activity of)
RN 221214-41-1 CAPLUS
CN Sulfamic acid, 4-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 221214-42-2 CAPLUS
CN Sulfamic acid, 4-[(1Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1996:169243 CAPLUS
DN 124:316749
TI N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IN Lee, Helen T.; Picard, Joseph A.; Sliskovic, Drago R.; Wierenga, Wendell
PA Warner-Lambert Company, USA
SO U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 62,515, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5491172	A	19960213	US 1994-223932	19940413
	IL 109431	A1	20010111	IL 1994-109431	19940426
	CA 2158268	AA	19941124	CA 1994-2158268	19940511
	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 72653	A2	19960528	HU 1995-2811	19940511
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	AT 178891	E	19990415	AT 1994-916734	19940511
	ES 2133163	T3	19990901	ES 1994-916734	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	ZA 9403313	A	19951113	ZA 1994-3313	19940513
	US 5633287	A	19970527	US 1995-546967	19951023
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	B2	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		

OS MARPAT 124:316749
AB The present invention is directed to title ACAT-inhibiting compds. R1XSO2NRCOYR2 useful for the regulation of cholesterol, methods for using them and pharmaceutical compns. thereof, wherein: X and Y are oxygen, sulfur, or (CR'R'')n wherein n is 1 to 4 and R' and R'' are each independently, e.g., H, alkyl, alkoxy or R' and R'' together form a spirocycloalkyl or a carbonyl; R is hydrogen, alkyl, or benzyl; R1 and R2 are Ph, substituted Ph, naphthyl, substituted naphthyl, an aralkyl group, an alkyl chain, adamantyl, or a cycloalkyl group. Thus, e.g., hydroxyethylation of 2,6-diisopropylbromobenzene with Li/ethylene oxide afforded 2-(2,6-diisopropylphenyl)ethanol; Jones oxidn. of the latter afforded the (2,6-diisopropylphenyl)acetic acid; conversion to the acid chloride followed by amidation with 2,6-diisopropylphenyl sulfamate afforded ArCH2CONHSO2OAr (Ar = 2,6-diisopropylphenyl) which exhibited IC50 = 9.7 .mu.M for inhibition of ACAT in vitro and -63% change in mean cholesterol levels in vivo.
IT **166519-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(N-acyl sulfamic acid esters, N-acyl sulfonamides, and N-sulfonyl

carbamic acid esters as hypercholesterolemic agents)
RN 166519-18-2 CAPLUS
CN Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1995:742595 CAPLUS
DN 123:143436
TI N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IN Lee, Helen Tsenwhei; Picard, Joseph Armand; Sliskovic, Drago Robert; Wierenga, Wendell
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426702	A1	19941124	WO 1994-US5233	19940511
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5491172	A	19960213	US 1994-223932	19940413
	AU 9468311	A1	19941212	AU 1994-68311	19940511
	AU 681152	B2	19970821		
	EP 698010	A1	19960228	EP 1994-916734	19940511
	EP 698010	B1	19990414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08510256	T2	19961029	JP 1994-525674	19940511
	RU 2137756	C1	19990920	RU 1995-122768	19940511
	FI 9505438	A	19951110	FI 1995-5438	19951110
	NO 9504564	A	19960111	NO 1995-4564	19951113
PRAI	US 1993-62515	A	19930514		
	US 1994-223932	A	19940413		
	WO 1994-US5233	W	19940511		

OS MARPAT 123:143436
AB Compds. of formula R1XS(O2)NRCOYR2 (R = H, C1-8 alkyl, benzyl; R1, R2 = Ph, phenoxy, naphthyl, arylalkyl, C1-20 alkyl, etc.; X, Y = O, S, alkyl), or their salts, are useful for the regulation of plasma cholesterol. Compds. may be used for treatment of hypercholesterolemia and atherosclerosis. Prepn. of 48 compds. is presented.
IT **166519-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of acyl sulfamic acid esters (or thioesters), acyl sulfonamides, and sulfonyl carbamic acid esters (or thioesters) as antihypercholesterolemic agents)
RN 166519-18-2 CAPLUS
CN Sulfamic acid, [1,1':3',1''-terphenyl]-2'-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1995:662328 CAPLUS
DN 123:83996
TI Preparation of amino acid derivatives as neuropeptide Y antagonists.
IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Mihm, Gerhard; Doods, Henri; Wieland, Heike-Andrea; Willim, Klaus-Dieter; Krause, Juergen; Dollinger, Horst; et al.
PA Dr. Karl Thomae GmbH, Germany
SO PCT Int. Appl., 308 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9417035	A1	19940804	WO 1994-EP109	19940118
	W: AU, BG, BY, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RO, RU, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 4301452	A1	19940721	DE 1993-4301452	19930120
	DE 4326465	A1	19950209	DE 1993-4326465	19930806
	AU 9458841	A1	19940815	AU 1994-58841	19940118
	AU 683442	B2	19971113		
	EP 680469	A1	19951108	EP 1994-905073	19940118
	EP 680469	B1	20000426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08505862	T2	19960625	JP 1994-516636	19940118
	AT 192142	E	20000515	AT 1994-905073	19940118
	FI 9503467	A	19950718	FI 1995-3467	19950718
	NO 9502869	A	19950919	NO 1995-2869	19950719
PRAI	DE 1993-4301452	A	19930120		
	DE 1993-4326465	A	19930806		
	WO 1994-EP109	W	19940118		

OS MARPAT 123:83996
AB TZNR1CR2R3COY(CH2)nR [n = 0-5; R = H, OH, (substituted) Ph, naphthyl, aminophenyl, aminonaphthyl, hydroxyphenyl, hydroxynaphthyl, diphenylmethyl, heteroaryl, cycloalkyl, etc.; Y = O, NR4; R1, R4 = H, alkyl, cycloalkyl, (substituted) Ph, PhCH2; R2 = substituted alkyl, Ph, PhCH2; R3 = H, alkyl, cycloalkyl; T = H, Ph, (substituted) heteroaryl, protecting group, etc.; Z = bond, CO, CH2, SO, SO2], were prepd. Thus, H-D-Arg(NO2)-OH in THF was treated with aq. NaOH and then with Ph2CHCOCl to give 85% amide. This in THF was treated with N-methylmorpholine, iso-Bu chloroformate, and 4-(aminomethyl)acetanilide under cooling to give 63% (R)-N-[[4-(acetylamino)phenyl]methyl]-N5-[amino(nitroimino)methyl]-N2-(diphenylacetyl)ornithinamide. This was hydrogenated in aq. HOAc over Pd to give (R)-N-[[4-(acetylamino)phenyl]methyl]-N2-diphenylacetylargininamide acetate. Title compds. antagonized neuropeptide Y-induced effects on blood pressure in rats at 0.01-10 mg/kg.
IT **164643-39-4P 164645-11-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as neuropeptide Y antagonists)
RN 164643-39-4 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[[[5-[(aminoiminomethyl)amino]-2-[(diphenylacetyl)amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 164645-11-8 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[[[5-[(aminoiminomethyl)amino]-2-[(diphenylacetyl)amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 164643-39-4
CMF C29 H36 N6 O5 S

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



IT **164647-52-3P 164647-54-5P 164647-55-6P 164648-83-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of amino acid derivs. as neuropeptide Y antagonists)
RN 164647-52-3 CAPLUS
CN Carbamic acid, [1-[[[[4-[[(dimethylamino)sulfonyl]oxy]phenyl]methyl]amino]carbonyl]-4-[[imino(nitroamino)methyl]amino]butyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 164647-54-5 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[[[2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 164647-53-4
CMF C15 H25 N7 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 164647-55-6 CAPLUS
CN Sulfamic acid, dimethyl-, 4-[[[2-[(diphenylacetyl)amino]-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]amino]methyl]phenyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 164648-83-3 CAPLUS
CN Sulfamic acid, dimethyl-, 4-(aminomethyl)phenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L12 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1995:508003 CAPLUS
DN 122:265364
TI Preparation of 4-phenyloxazole and -thiazole derivatives as herbicides
IN Nakanishi, Hiroyuki; Miura, Juzo; Nishioka, Hitoshi; Ootsuka, Takashi
PA Nihon Nohyaku Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06340643	A2	19941213	JP 1994-89169	19940404
PRAI JP 1993-101921		19930404		

OS MARPAT 122:265364
AB The title compds. [I; R1 = halo, NO2, C1-6 alkyl, halosulfonyl, BR4, NR5; wherein B = O, S(O)n (n = 0-2); R4 = H, C1-6 (halo)alkyl, C1-6 hydroxyalkyl, C2-6 (halo)alkenyl, C2-6 (halo)alkynyl, C3-6 (halo)cycloalkyl, etc.; R5 = H, C1-6 (halo)alkyl, C2-6 (halo)alkenyl, C2-6 (halo)alkynyl, C3-6 cycloalkyl, C1-6 (halo)alkylsulfonyl, phenyl-C1-6 alkyl, etc.; R2 = HO, C1-6 (halo)alkyl, C1-6 cycloalkyl, C1-6 (halo)alkoxy, C1-6 alkoxy-C1-6 alkyl, C1-6 alkylthio-C1-6 alkyl; R3 = H, halo; A = O, S; X, Y = halo, C1-6 (halo)alkyl], which show excellent herbicidal activity against post- and preemergence weeds, are prepd. Thus, 3.10 g 1-bromo-2-phenyl-2-ethanone deriv. (II) and 2.61 g isobutyramide were heated at 150-160.degree. for 5.5 h to give, after silica gel chromatog., 81.9% title compd. I (R1 = iso-ProO, R2 = iso-Pr, R3 = H; X, Y = 2-F, 4-Cl). I (R1 = OCH2C.tplbond.CH, R2 = iso-Pr, R3 = Cl; X, Y = 2-F, 4-Cl) at 1 kg/ha postemergence controlled .gtoreq.95% Echinochloa crus-galli in a flooded paddy soil and gave no damage to rice. A total of 165 I were prepd.
IT **162504-19-0P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenyloxazole or -thiazole deriv. as herbicide)
RN 162504-19-0 CAPLUS
CN Sulfamic acid, methyl-, 2-chloro-5-(5-chloro-2-propyl-4-thiazolyl)-4-fluorophenyl ester (9CI) (CA INDEX NAME)



L12 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1993:516981 CAPLUS
DN 119:116981
TI Preparation of N-cyclohexyl-N-benzylguanidines as fungicides
IN Ishikawa, Hiromichi; Umeda, Ten; Hara, Takashi; Kajikawa, Kazuo
PA Hokko Chem Ind Co, Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05058986	A2	19930309	JP 1991-240236	19910828
PRAI JP 1991-240236		19910828		

OS MARPAT 119:116981
AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, alkanoyl, etc.; R2 = alkyl; R3, R4 = H, alkyl, alkenyl, alkynyl, or NR3R4 = N-contg. heterocyclyl; X = H, halo, alkyl, alkoxy] are prepd. E.g., I [R1 = X = H, R2 = Me2CH, R3 = R4 = Me] was treated with p-MeC6H4SO2Cl in THF contg. NaH at room temp. for 1 h to give the title compd. I [X = H, R1 = p-MeC6H4SO2, R2 = Me2CH, R3 = R4 = Me], which at 100 ppm showed 100% kill of Pseudoperonospora cubensis. Many agricultural fungicidal prepns. contg. I are described.
IT **149429-65-2P 149429-71-0P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as fungicide)
RN 149429-65-2 CAPLUS
CN Sulfamic acid, dimethyl-, 2-[[cyclohexyl[(dimethylamino)(phenylimino)methyl]amino]methyl]-4-(1-methylethyl)phenyl ester (9CI) (CA INDEX NAME)



RN 149429-71-0 CAPLUS
CN Sulfamic acid, diethyl-, 2-[[cyclohexyl[imino(phenylamino)methyl]amino]methyl]-4-(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)


NH
t-Bu
C
NHPh
N
CH2
O
S
NEt2
O
O

L12 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1982:217218 CAPLUS
DN 96:217218
TI Versatile synthesis of sulfamate esters by phase-transfer methods
AU Spillane, William J.; Taheny, Anne P.; Kearns, M. Mary
CS Chem. Dep., Univ. Coll. Galway, Galway, Ire.
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1982), (3), 677-9
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
AB Sulfamate esters, R2NSO3R1 (R = Me, Et), RNHSO3R1 (R = cyclohexyl), and H2NSO3R1 (R1 = alkyl, aryl) were prepd. by condensation of the appropriate sulfamoyl chloride with alcs. and phenols under mild phase-transfer conditions. E.g., reaction of Me2NSO2Cl with MeOH in C6H6 contg. PhCH2N+Et3Cl- and aq. NaOH at 50.degree. for 2 h gave 90% Me2NSO3Me. Me2NSO3R (R = Me, Et, Pr, CMe3) rearranged to the corresponding betaines Me2N+RSO3- in 95-98% yield at 130.degree..
IT **72119-30-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, by condensation of sulfamoyl chloride with phenol)
RN 72119-30-3 CAPLUS
CN Sulfamic acid, diethyl-, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1982:199210 CAPLUS
DN 96:199210
TI 2-(Aminomethyl)phenols, a new class of saluretic agents. 4. Effects of oxygen and/or nitrogen substitution
AU Stokker, G. E.; Deana, A. A.; DeSolms, S. J.; Schultz, E. M.; Smith, R. L.; Cragoe, E. J., Jr.; Baer, J. E.; Russo, H. F.; Watson, L. S.
CS Merck Inst. Ther. Res., Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA
SO Journal of Medicinal Chemistry (1982), 25(6), 735-42
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB A series of O and/or N-substituted 2-(aminomethyl)phenols was synthesized and tested orally in rats for saluretic and diuretic effects. In general, substitution on N with groups other than lower alkyl or substitution on N and/or O with groups resistant to hydrolysis substantially diminished saluretic effects.
IT **68967-66-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)
RN 68967-66-8 CAPLUS
CN Carbamic acid, [[2-[[(dimethylamino)sulfonyl]oxy]-5-(1,1-dimethylethyl)-3-iodophenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **68967-67-9P 68967-74-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and diuretic activity of)
RN 68967-67-9 CAPLUS
CN Sulfamic acid, dimethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN. 68967-74-8 CAPLUS
CN Sulfamic acid, ethyl-, 2-(aminomethyl)-4-(1,1-dimethylethyl)-6-iodophenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L12 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1980:6189 CAPLUS
DN 92:6189
TI Study of the reactivity of aryl fluorosulfates with respect to secondary aliphatic amines
AU Hedayatullah, Mir; Guy, Alain
CS Lab. Chim. Org., Conservatoire Natl. Arts Metiers, Paris, 75141/03, Fr.
SO Phosphorus and Sulfur and the Related Elements (1979), 7(1), 95-100
CODEN: PREEDF; ISSN: 0308-664X
DT Journal
LA French
AB Aryl sulfamates are obtained from aryl fluorosulfates and secondary aliph. amines. The use of the HSAB concept (Hard and Soft Acids and Bases) is used to explain the difference of the reactivity between aryl fluorosulfates and aryl chlorosulfates.
IT **72119-30-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 72119-30-3 CAPLUS
CN Sulfamic acid, diethyl-, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1978:442661 CAPLUS
DN 89:42661
TI A convenient synthesis of aryl sulfamates
AU Hedayatullah, Mir; Guy, Alain
CS Lab. Chim. Org., Conservatoire Natl. Arts Metiers, Paris, Fr.
SO Synthesis (1978), (5), 357
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
AB RnC6H5-nO3SNH2 (Rn = H, 2-, 4-Me, 2,6-Me2, 2-, 4-Ph, 4-Cl) were prepd. in 50-75% yield by NaBH4 redn. of RnC6H5-nO3SN3.
IT **25999-01-3P 67073-77-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



RN 67073-77-2 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-2-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1975:547252 CAPLUS
DN 83:147252
TI Synthesis and reduction of aryl azidosulfates. VI
AU Hedayatullah, Mir; Guy, Alain
CS Lab. Chim. Org. Appl., Conservatoire Natl. Arts Metiers, Paris, Fr.
SO Tetrahedron Letters (1975), (29), 2455-8
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA French
AB Reaction of p-RC6H4OSO2Cl (R = H, Me, Cl, Ph) with NaN3 in MeCN gave 90-8% p-RC6H4OSO2N3 (I) which in MeOH with powd. Cu gave 47-86% p-RC6H4OSO2NH2. LiAlH4 redn. of I gave the corresponding phenols by cleavage of the O-S bond.
IT **25999-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1972:539511 CAPLUS
DN 77:139511
TI Preparation and reactions of aryloxysulfonyl isocyanates
AU Lohaus, Gerhard
CS Farbwerke Hoechst A.-G., Frankfurt/M., Fed. Rep. Ger.
SO Chemische Berichte (1972), 105(9), 2791-9
CODEN: CHBEAM; ISSN: 0009-2940
DT Journal
LA German
AB Re-action of phenols ROH (e.g. R = Ph, p-MeC6H4, m-ClC6H4, 2,4,6-Cl3C6H2, p-NCC6H4) with ClSO2NCO gave 40-79% ROSO2NCO (I). Hydrolysis of I yielded nearly quant. ROSO2NH2 (II). I are highly active compds. and the reactivity corresponded to the acidity of the starting phenols. II was useful for the transfer of SO2NH2 groups, e.g. to amines.
IT **25999-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1971:127560 CAPLUS
DN 74:127560
TI 3-Substituted-7-aminocoumarins, as optical brighteners or their intermediates
PA Farbenfabriken Bayer A.-G.
SO Fr. Demande, 12 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2016308		19700508		
PRAI DE		19680823		

AB Title compds. (I) are prepd. by heating the corresponding 5,2,4-R1(RO)(H2N)C6H2CH:C(R2)CN (II, R = SO2NMe2 or CH2OMe) (cf. Fr. Demande 2,016,307) with aq. mineral acids at 104-55.degree. for 6-10 hr. Thus II (R1 = H, R2 = Ph, R = Me2NSO2) was heated in 62% H2SO4 at 130.degree. for 7 hr to give I (R1 = H, R2 = Ph). Similarly 10 other I were prepd.

IT **31804-41-8P 31804-42-9P 31804-43-0P**
31804-44-1P 31804-45-2P 31804-51-0P
RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 31804-41-8 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)



RN 31804-42-9 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-p-tolylacrylonitrile (8CI) (CA INDEX NAME)



RN 31804-43-0 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-methoxyphenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-44-1 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-chlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-45-2 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(3,4-dichlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-51-0 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-6-hydroxy-m-tolyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)



L12 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1971:113267 CAPLUS
DN 74:113267
TI Substituted .beta.-phenylacrylonitrile derivatives as intermediates for optical brighteners
PA Farbenfabriken Bayer A.-G.
SO Fr. Demande, 13 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2016307		19700508		
PRAI DE		19680823		

AB 5,2,4-R1(RO)(O2N)C6H2Me are treated with Na2Sx in ROH or Me2SO at 50-120.degree. 0.5-3 hr to give 5,2,4-R1-(RO)(H2N)C6H2CHO, which react with R2CH2CN at 20-120.degree. to give the title products (I) which can be converted into the corresponding coumarins by heating with aq. mineral acid at 80-200.degree. (cf. Fr. Demande 2,016,308). Thus, an aq. soln. of Na2S, NaOH, and S was added dropwise to a boiling aq. alc. soln. of 2,4-MeO(O2N)C6H3Me, the mixt. boiled for 0.5 hr, treated with PhCH2CN, and boiled for 1 hr to give I (R = Me, R1 = H, R2 = Ph). Similarly, 16 other I were prepd.

IT **31804-41-8P 31804-42-9P 31804-43-0P**
31804-44-1P 31804-45-2P 31804-51-0P
RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 31804-41-8 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)



RN 31804-42-9 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-p-tolylacrylonitrile (8CI) (CA INDEX NAME)



RN 31804-43-0 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-methoxyphenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-44-1 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(p-chlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-45-2 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-2-hydroxyphenyl)-2-(3,4-dichlorophenyl)acrylonitrile (8CI) (CA INDEX NAME)



RN 31804-51-0 CAPLUS
CN Sulfamic acid, dimethyl-, ester with 3-(4-amino-6-hydroxy-m-tolyl)-2-phenylacrylonitrile (8CI) (CA INDEX NAME)


H2N
O
S
NMe2
O
O
Me
CH
C
CN
Ph

L12 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1970:55051 CAPLUS
DN 72:55051
TI Sulfamic acid aryl esters
PA Farbwerke Hoechst A.-G
SO Fr., 3 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 1554976		19690124		
PRAI DE		19670128		

AB Isocyanates Ar(OSO2NCO)n (where Ar = aryl, n = 1 or 2) (Ger. 1,230,017) react with H2O to yield aryl sulfamate N-carboxylic acids which lose CO2 spontaneously to form Ar(OSO2NH2)n (I). Thus, 15 g H2O is added dropwise to 64 g 4-NCC6H4OSO2NCO in 500 ml CCl4 to ppt. 55 g 4-NCC6H4-OSO2NH2, m. 155.degree.. Other I (n = 1) prepd. are the following (Ar and m.p. given): 4-ClC6H4, 105.degree.; 3-ClC6H4, 80.degree.; Ph, 86.degree.; 4-MeC6H4, 80.degree.; 3-MeC6H4, 88.degree.; 2,6-Me2C6H3, 110.degree.; 2,3-Me2-C6H3, 78.degree.; 2,5-Me2C6H3, 104.degree.; 2,4,5-Cl3C6H2 (II), 158.degree.; 2,4,6-Cl3C6H2, 144.degree.; 2,4,6-Br3C6H2, 164.degree.; C6Cl5, 215.degree.; 4-MeO-C6H4, 165.degree.; 4-PhN2C6H4, 160.degree.; the sulfonate of 3-hydroxydibenzofuran, 156.degree.; and hydroquinone bis(sulfamate), 200.degree.. The compds. are useful for transferring the sulfonamide group. Thus, by shaking 1.35 g II with 0.9 g morpholine in 5 ml CH2Cl2, the ester dissolves to yield 0.71 g morpholine-N-sulfonamide, m. 160.degree..

IT **25999-01-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 25999-01-3 CAPLUS
CN Sulfamic acid, [1,1'-biphenyl]-4-yl ester (9CI) (CA INDEX NAME)



L12 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1965:43634 CAPLUS
DN 62:43634
OREF 62:7670a-c
TI Synthesis and anticholinesterase activity of a series of aryl N,N-dimethylsulfamates
AU Corral, C.; Municio, A. M.
CS Inst. Quim., Madrid
SO Anales Real Soc. Espan. Fis. Quim. (Madrid) (1964), Ser. B 60(4), 341-4
DT Journal
LA Unavailable
AB A series of N,N-dimethylsulfamates was prepd. Thus, 0.03 mole corresponding phenol was exactly neutralized with 2N NaOH and the soln. evapd. to dryness on a steam bath in vacuo. To the dry phenolate was added 50 ml. anhyd. EtCOMe and 0.03 mole MeNSO2Cl and the mixt. rerefluxed 8 hrs. to give the following aryl N,N-dimethylsulfamates [aryl group and m.p. and (or) b.p./mm. given]: 1-naphthyl, 77.degree., 90.degree./0.1; 2-naphthyl, 73.degree.; 2-cyclohexylphenyl, 62.degree.; 2-phenylphenyl, 78.degree.; 3-methylcoumaryl, 151.degree.; 3-pyridyl, 99.degree./0.25; 2-methylphenyl, 95.degree./0.1; 3-methylphenyl, 94.degree./0.1; 4-methylphenyl, 95.degree./0.1; 2-methoxyphenyl, 38-42.degree., 120.degree./0.5; 3-methoxyphenyl, 124.degree./0.1; 4-methoxyphenyl, 140.degree./1; 2-isopropoxyphenyl, 125.degree./0.5; 2-chlorophenyl, 38.degree., 98.degree./0.05; 3-chlorophenyl, 105.degree./0.1; 4-chlorophenyl, 46.degree., 102.degree./0.5; 2-nitrophenyl, 66.degree.; 3-nitrophenyl, 85.degree.; 4-nitrophenyl, 124.degree.; 2-carbethoxyphenyl, 128.degree./0.1; 3-carbethoxyphenyl, 130.degree./0.05; 4-carbethoxyphenyl, 136.degree./0.1; 3-ethyl-5-methylphenyl, 124.degree./0.5; carvacryl, 122.degree./0.05; isothymyl, 105.degree./0.1; thymyl, 108.degree./0.1; 3,5-dichlorophenyl, 106.degree./0.1; 3,4-dichlorophenyl, 60.degree.; 2,3-dichlorophenyl, 73.degree.; 4-chloro-3-methylphenyl, 28.degree.; 4-nitro-3-methylphenyl, 67.degree.; 2,4,5-trichlorophenyl, 85.degree.; 2,3,5-trimethylphenyl, 72.degree.; 4,6-dichloro-3-methylphenyl, 118.degree./0.1. None of the esters showed anticholinesterase activity at 10-3M concn. The 3,5-dichlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3-chlorophenyl, and Ph esters showed, in decreasing order, the greatest insecticidal activity. The rest were much less active.
IT **1151-28-6**, Sulfamic acid, dimethyl-, 2-biphenylyl ester (anticholinesterase activity of)
RN 1151-28-6 CAPLUS
CN Sulfamic acid, dimethyl-, 2-biphenylyl ester (7CI, 8CI) (CA INDEX NAME)



L12 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2003 ACS
AN 1963:408988 CAPLUS
DN 59:8988
OREF 59:1636b-f
TI N,N-Bis-(2-chloroethyl)sulfoamines
AU Preussmann, Rudolf
SO Arzneimittel-Forsch. (1962), 12, 1119-23
DT Journal
LA Unavailable
AB The prepn. of 21 derivs. of N,N-bis(2-chloroethyl)sulfoamines, which are nitrogen mustard derivs. of sulfuric acid, was reported. The lability of chlorine and the therapeutic effect on the transplanted Yoshida sarcoma in rats was detd. and correlations between the chem. structure and biol. effects were discussed. To a soln. of 36 g. COCl2 in 300 ml. C6H6 was added a soln. of bis(2-chloroethyl)-amine, prepd. from 70 g. HCl salt, and 54 ml. Et3N dropwise, with cooling and stirring at 10.degree.. The mixt. was kept 2 hrs. at room temp., Et3N.HCl filtered off, the C6H6 soln. washed with aq. acid, NaHCO3, and H2O, and dried with Na2SO4 to give Z2NCOCl (Z = ClCH2CH2 throughout abstr.) (I), b2 118.degree. (81% yield). I (150 g.) was treated with 59 g. SO3 3 hrs. at room temp. and warmed on a water bath at 80.degree. to remove CO2. The mixt. was extd. with Et2O and the ext. washed with NaHCO3 and H2O to give 158 g. Z2NSO2Cl (II), b5 126.degree.. II treated with NaOMe gave 83% Z2NSO3Me, b4 143-5.degree.. II and NaOPh gave Z2NSO3-Ph. Diethylstilbestrol (4.5 g.) was treated with a soln. of 0.8 g. Na in 40 ml. MeOH, refluxed 10 min., and pptd. with H2O to give (p-Z2NSO3CEt:)2 (6 g.), m. 122-4.degree.(MeOH). II (33 g.) was treated with 6 g. NH3 in 600 ml. dioxane, the mixt. held overnight at room temp., and NH4Cl filtered off to give 45% Z2NSO2-NH2, m. 82.5-3.5.degree.. Glycine ester (5.2 g.), 6.9 ml. Et3N, and 12 g. II in 50 ml. dioxane was kept overnight at room temp. to give after filtration of Et3N.HCl 9 g. Z2NSO2NHCH2CO2Et, m. 61-3.degree. (aq. EtOH). Similarly were prepd. (Z2NSO2NHCH2)2, m. 75.degree., [Z2NSO2NH(CH2)3]2, m. 124.degree. (EtOH), Z2NSO2NEt2, oil; Z2NSO2NZ2, oil; IIa, m. 138.5-9.5.degree. (EtOH), Z2NSO2NHNH2 (III), m. 100-1.degree. (Et2O-petr. ether); HCl salt m. 116-18.degree.. III (23.6 g.) refluxed with 0.1 mole of aldehyde or ketone in Et2O 2 hrs. yielded 60-90% of the hydrazone Z2NSO2NHN:R (R and m.p. given): Me2C, 81.5.degree.; MeCCH2CO2Et, 75-6.degree.; MeCCH2CH2CO2H, 117-18.degree.; HOCH2(CH2OH)4CH(from glucose), 65-70.degree.; MeCAc, 76.5-7.5.degree.; p-Me2NC6H4CH, 144.5-5.5.degree. (oxalate m. 155-5.5.degree.); 3-methylenepyridine, 121-2.degree. (HCl salt 132-3.degree.). Acetylacetone (2 g.) in 5 ml. EtOH was added to 5.5 g. III in 15 ml. 2N HCl and 10 ml. EtOH at 0.degree. to give IV. Also prepd. was (Z2NSO2NHN:CMe)2, m. 167.5-8.5.degree.. The lability of chlorine was detd. of a 0.23M soln. in dioxane with 6M NaHCO3 at 37.degree..
IT **102584-76-9**, Sulfamic acid, bis(2-chloroethyl)-, diester with .alpha.,.alpha.'-diethyl-4,4'-stilbenediol
(prepn. of)
RN 102584-76-9 CAPLUS
CN Sulfamic acid, bis(2-chloroethyl)-, (1,2-diethyl-1,2-ethenediyl)di-4,1-phenylene ester (9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 14:11:00 ON 13 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 14:11:07 ON 13 MAY 2003
L1                STRUCTURE UPLOADED
L2             50 S L1 SSS SAM
L3                SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L4                STRUCTURE UPLOADED
L5                QUE L4 NOT L3
L6             50 S L5 SSS SAM
L7                SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L8                STRUCTURE UPLOADED
L9                QUE L8 NOT L7
L10            10 S L9 SSS SAM
L11           255 S L9 SSS FUL

     FILE 'CAPLUS' ENTERED AT 14:26:49 ON 13 MAY 2003
L12            42 S L11

     FILE 'CAOLD' ENTERED AT 14:28:03 ON 13 MAY 2003

=> s l11
L13             4 L11

=> d l13 1-4 bib,hitstr
```

L13 ANSWER 1 OF 4 CAOLD COPYRIGHT 2003 ACS
AN CA62:7670a CAOLD
TI synthesis and anticholinesterase activity of a series of aryl N,N-dimethylsulfamates
AU Corral, C.; Martin Municio, A.
IT **1151-28-6**
RN 1151-28-6 CAOLD
CN Sulfamic acid, dimethyl-, 2-biphenylyl ester (7CI, 8CI) (CA INDEX NAME)



L13 ANSWER 2 OF 4 CAOLD COPYRIGHT 2003 ACS
AN CA59:3853b CAOLD
TI aromatic carboxylic acids
AU Juettner, Bernhard; Benning, A.
DT Patent
TI carboxylic acids (aromatic)
PA Bergwerksverband G.m.b.H.
DT Patent

PATENT NO.	KIND	DATE
DE 1136687		

IT **101547-37-9**
RN 101547-37-9 CAOLD
CN Sulfamic acid, dipropyl-, 4,4'-biphenylylene ester (7CI) (CA INDEX NAME)



L13 ANSWER 3 OF 4 CAOLD COPYRIGHT 2003 ACS
AN CA59:3852g CAOLD
TI aryl dialkylsulfamates
AU Dunbar, Joseph E.
PA Dow Chemical Co.
DT Patent

PATENT NO.	KIND	DATE
US 3082238		1963

IT **98176-69-3**
RN 98176-69-3 CAOLD
CN Sulfamic acid, dimethyl-, 4,4'-biphenylylene ester (7CI) (CA INDEX NAME)



L13 ANSWER 4 OF 4 CAOLD COPYRIGHT 2003 ACS
AN CA59:1636b CAOLD
TI N,N-bis-(2-chloroethyl)sulfoamines
AU Preussmann, Rudolf
IT **102584-76-9**
RN 102584-76-9 CAOLD
CN Sulfamic acid, bis(2-chloroethyl)-, (1,2-diethyl-1,2-ethenediyl)di-4,1-phenylene ester (9CI) (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                10.88     360.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00     -27.34

STN INTERNATIONAL LOGOFF AT 14:28:38 ON 13 MAY 2003
```